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ABSTRACT 
 
REGULATION AND KINASE ACTIVITY OF THE TRK FAMILY OF RECEPTOR 
TYROSINE KINASES 
Stephen C. Artim 
Mark A. Lemmon 
The tropomyosin-related kinase (Trk) family consists of three receptor tyrosine kinases 
(RTKs) called TrkA, TrkB, and TrkC. These RTKs are regulated by the neurotrophins, a 
class of secreted growth factors responsible for the development and function of 
neurons.  Given the high homology between the Trks and their use of overlapping 
signaling pathways, the key question to be addressed is how the activation of the 
different Trks can lead to distinct cellular outcomes. To this end, I first sought to 
determine the mechanism of autoregulation for the Trk tyrosine kinase domain (TKD). 
The Trk TKDs are members of the insulin receptor kinase (IRK) superfamily and recent 
data suggest that the IRK family displays a wide array of autoinhibitory mechanisms. To 
determine where TrkA and the closely related Ror2 TKD (from an unconventional Wnt 
receptor) lie in this spectrum, we determined the crystal structures of the kinase domains 
of these RTKs. In both cases, the conformation of the activation loop resembles the IRK 
activation loop conformation, with subtle but notable differences in the case of Ror2. 
These findings aid in understanding the range of autoinhibitory mechanisms of the IRK 
family, in addition to providing a foundation for deciphering consequences of TKD 
mutations in this family. I also observed crystallographic dimers of the inactive TrkA TKD 
that resemble those seen for other RTK TKDs – which may aid in understanding the 
reported pre-formed inactive TrkA dimers observed in cells. To understand the molecular 
basis for differences in signaling specificity of the Trk receptors, I investigated whether 
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the TrkA and TrkB TKDs differ in their intrinsic kinase activities. I show that the TrkA 
TKD autophosphorylates itself faster than its TrkB counterpart. However, this difference 
of autophosphorylation is not due to a difference in kinase activity per se. Rather, my 
data indicate that the difference in autophosphorylation may arise because of self-
association of the TrkA TKD that does not occur with TrkB. My work sheds light on 
potential differences between TrkA and TrkB signaling, as well as providing a 
quantitative understanding of Trk TKD activation, which is useful for effective and 
selective inhibitor design. 
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Chapter 1:  
Introduction 
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1.1 Cellular communication mediated by Receptor Tyrosine Kinases (RTKs) 
 
The ability of cells to interpret extracellular clues and respond accordingly either by 
proliferating, migrating, or differentiating is crucial for maintaining homeostasis. A major 
advance in understanding how cells communicate with surrounding cells and the 
environment occurred in the 1950s when Rita Levi-Montalcini and Stanley Cohen 
discovered the first soluble growth factor from mouse salivary-gland extracts and snake 
venom (Cohen and Levi-Montalcini, 1957; Levi-Montalcini, 1952; Levi-Montalcini and 
Cohen, 1960). This growth factor was termed nerve growth factor (NGF), since applying 
NGF to cells resulted in neurite outgrowth. However, understanding of how the cells 
recognize NGF and respond accordingly remained elusive. In the early 1960s, Cohen 
then discovered another growth factor termed epidermal growth factor (EGF) (Cohen, 
1962; 1965), but how NGF and EGF dictated the cellular response remained a mystery. 
In 1978, Cohen and co-workers demonstrated the existence of a specific receptor for 
EGF (the EGF receptor or EGFR) and showed that, upon binding of EGF, there was an 
increase of cellular phosphorylation (Carpenter et al., 1978). Twenty years earlier, Gene 
Kennedy had described the first protein kinase by discovering that a liver enzyme 
catalyzed the phosphorylation of a protein, casein (Burnett and Kennedy, 1954). 
Subsequently, Fischer and Krebs discovered that phosphorylase kinase catalyzes the 
transfer of a gamma phosphate from ATP to a serine side-chain in phosphorylase b, 
(Fischer and Krebs, 1955; Fischer et al., 1959; Krebs and Fischer, 1956). Also during 
this time, phosphatases were identified as enzymes that remove phosphates from 
proteins. These discoveries in the 1970s and 1980s solidified the idea that the reversible 
modifications of phosphorylation and dephosphorylating catalyzed by kinases and 
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phosphatases represent a wide and significant mechanism utilized to modify protein 
function (Cohen, 2002).  
Many of the initial studies showed that phosphorylation only occurs on serine or 
threonine residues. However, the discovery that the Rous sarcoma viral protein kinase, 
v-src, was responsible for transformation (Collett and Erikson, 1978) led Tony Hunter to 
discover that v-src phosphorylated proteins on tyrosine residues (Hunter and Sefton, 
1980). These studies also showed that deregulated tyrosine kinase activity is involved in 
tumorigenesis (Gschwind et al., 2004; Hunter and Eckhart, 2004).  
In the 1980s, data from various groups working on EGFR (Ushiro and Cohen, 1980), 
insulin receptor (IR) (Kasuga et al., 1982), and platelet-derived growth factor receptor 
(PDGFR) (Ek et al., 1982) demonstrated that growth factors bind and activate receptors 
with intrinsic tyrosine kinase activity. Surprisingly, the major substrates for 
phosphorylation by RTKs were shown to be the RTKs themselves (Cohen, 2002). In the 
late 1980s, Tony Pawson discovered the existence of src homology-2 (or SH2) domains 
as non-catalytic domains crucial for modulating signaling effects of tyrosine kinases. He 
and others then showed that SH2 domains recognize specific phosphorylated tyrosines 
on RTKs and other signaling proteins (Anderson et al., 1990; Sadowski et al., 1986). 
Upon ligand binding, autophosphorylation of dimeric RTKs creates tyrosine 
phosphorylated motifs recognized by SH2 domains and protein tyrosine binding (PTB) 
domains. During the 1990s, various studies culminated in a mechanistic link between 
RTKs and signaling cascades such as the small GTPase Ras – mitogen activated 
kinase (MAPK) pathway, ultimately leading to gene transcription that results in an array 
of cellular responses depending on the RTK and ligand (Cohen, 2002; Gschwind et al., 
2004). These discoveries revealed that RTKs transmit extracellular information to the 
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interior of the cell by initiating a kinase-dependent signaling cascade that ultimately 
leads to a cellular response according to the extracellular stimulus. 
Also in the 1990s, the receptor for NGF was determined to be Trk, a tyrosine kinase 
originally identified as tropomyosin-related kinase (trk), discovered previously in colon 
cancer (Kaplan et al., 1991a; 1991b; Klein et al., 1991a). It was later revealed that the trk 
oncogene was a fusion protein of dimerizing domains of non-muscle tropomyosin and 
the tyrosine kinase domain (TKD) of the TrkA receptor (Greco et al., 2010). Other 
neurotrophin ligands and receptors have been discovered and now the Trk RTK family 
consists of three members: TrkA, TrkB, and TrkC (Barbacid, 1994). 
The RTK family in humans is now known to comprise 58 members that fall into 20 
different families.  Most RTKs play key roles in crucial cellular processes such as 
proliferation and differentiation, cell migration, cell-cycle control, cell survival and 
metabolism (Gschwind et al., 2004; Lemmon and Schlessinger, 2010). 
 
1.2.  Role of the Trk family in the nervous system 
 
The Trk family of neurotrophin receptors is crucial for the development and maintenance 
of the nervous system. The family consists of three members, TrkA (NTRK1), TrkB 
(NTRK2) and TrkC (NTRK3). Neurotrophin ligands primarily bind to specific receptors – 
nerve growth factor (NGF) to TrkA, brain-derived neurotrophic factor (BDNF) and 
neurotrophin-4/5 (NT4) to TrkB, and neurotrophin-3 (NT3) to TrkC (Brodeur et al., 2009). 
Evolutionarily, RTK appearance is thought to coincide with the transition to 
multicellularity, allowing complex interactions to occur between cells and their 
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environments (Casaletto and McClatchey, 2012; King, 2004). Indeed, homologues of 
most RTKs exist in Drosophila and in C. elegans (Sopko and Perrimon, 2013).  
However, Trk signaling has been considered a vertebrate innovation due to the lack of 
evidence of Trk receptors in many invertebrate species including Drosophila and C. 
elegans (Benito-Gutierrez et al., 2006). The lack of invertebrate Trk receptors was 
thought to be due a reduced need for plasticity in the nervous system of insects 
(Bothwell, 2006). However, evidence has been presented for the existence of Trk-related 
receptors in the marine mollusk (Aplysia californica), the snail (Lymnaea stagnalis) and 
recently in the amphioxus (Branchiostoma floridae) (Benito-Gutierrez et al., 2006), 
suggesting that there was a common ancestor that had some form of a Trk receptor 
(Sossin, 2006b).  One study argues that the common ancestral kinase was a precursor 
to the Trk, MuSK, Ror and discoidin domain receptor (DDR) families. A subsequent split 
is then thought to have created the DDR family and a common ancestor of Trk, MuSK, 
and Ror which eventually split into three separate families by the time of a bilaterian 
ancestor (Sossin, 2006a). 
In mammals, the expression of the neurotrophins and their receptors occurs at early 
stages of neurogenesis (Barbacid, 1994; Bartkowska et al., 2010). The expression of 
each Trk family member is complex and depends on the developmental stage and type 
of cell. Generally, TrkA expression is confined to very specific structures of the central 
nervous system (CNS) and peripheral nervous system (PNS), whereas TrkB and TrkC 
have more widespread expression in the CNS and PNS.  Interestingly, the expression of 
TrkA is often distinct from TrkB/TrkC expression in the CNS and PNS (Bartheld and 
Fritzsch, 2006). Moreover, TrkA expression is essential for the development of normal 
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sympathetic neurons. In contrast, TrkB is rarely expressed in sympathetic neurons 
(Brodeur et al., 2009). 
Knockout mice null for TrkA, TrkB, or TrkC demonstrated distinct, but some overlapping, 
abnormalities of the central and peripheral nervous system (Brodeur et al., 2009) – 
generally correlating with the known expression patterns. For example, TrkA knockout 
mice have severe cell loss and morphological changes in structures that were known to 
express TrkA, such as ganglia in the sympathetic nervous system. In contrast, TrkB 
knockout mice do not demonstrate morphological changes in structures known to 
express TrkB. This suggests that some of the functions of TrkB can be fulfilled by other 
mechanisms, perhaps TrkC, since TrkB/TrkC are co-expressed in many structures in the 
nervous system (Barbacid, 1994). 
The initial focus of Trk expression studies was restricted to neuronal cells.  However, it is 
now clear that Trk expression does occur in non-neuronal cells (Shibayama and 
Koizumi, 1996). The role of Trk family members in non-neuronal cells is not well 
understood. There are two isoforms of TrkA, differing by only six amino acids in the 
extracellular domain, which do have specific expression patterns. The TrkA isoform Ι 
contains 790 amino acids and is expressed in non-neuronal tissue, whereas isoform ΙΙ 
contains 796 amino acids and is expressed primarily in neuronal tissue (Barbacid, 1994; 
Barker et al., 1993). 
 
1.3. RTK structure and function 
	  
Each RTK consists of an extracellular region (ECR) that binds its regulatory ligand, a 
single transmembrane domain (TM) and an intracellular domain (ICD) that contains the 
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juxtamembrane region (JM), a tyrosine kinase domain (TKD), and a C-tail region (Figure 
1.1).  
Activation of RTKs involves ligand binding to the extracellular region, which leads to RTK 
oligomerization and resulting activation of the intracellular kinase domain.  The active 
kinase trans-autophosphorylates tyrosines in its neighboring ICD in the receptor dimer, 
thereby both enhancing catalytic activity and providing sites for the (SH2 domain-
dependent) recruitment of signaling molecules that subsequently activate downstream 
pathways controlling transcription, metabolism, cell cycle progression, and survival 
(Lemmon and Schlessinger, 2010; Schlessinger, 2003; Ullrich and Schlessinger, 1990). 
To prevent aberrant signaling, autoregulatory mechanisms appear to exist in all RTKs, 
which maintain the kinase domain in an inactive or autoinhibited conformation until it is 
activated by extracellular ligand-induced oligomerization (Hubbard, 2004; Schlessinger, 
2003; Ullrich and Schlessinger, 1990). 
Interestingly, there is a subset of RTKs such as the insulin receptor (IRK) and insulin like 
growth factor 1 receptor (IGF1R) that already exists at the plasma membrane as 
disulfide linked dimers (De Meyts, 2004; 2008). Furthermore, there are many reports of 
other RTKs such as EGFR (Chung et al., 2010; Clayton et al., 2005; Gadella and Jovin, 
1995), TrkA (Paul S Mischel, 2002; Shen and Maruyama, 2011), and TrkB (Shen and 
Maruyama, 2012) existing as pre-formed oligomers at the cell surface . The nature of 
these inactive oligomers is unclear, since it is still recognized that ligand binding is 
necessary to obtain a fully active RTK oligomer in which the constituent subunits are 
oriented in the correct conformation for optimal autophosphorylation and subsequent 
phosphorylation of downstream signaling molecules (Lemmon and Schlessinger, 2010).  
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Figure 1.1. RTK domain structure. ECR=Extracellular region, TM= Transmembrane 
domain, ICD = Intracellular domain, JM= Juxtamembrane region, TKD= tyrosine kinase 
domain, CT=C-tail 
	  
	  
1.4. Structure of the tyrosine kinase domain (TKD) 
 
In 1991, the first protein kinase X-ray crystal structure was solved when Taylor and 
coworkers solved the structure of cAMP dependent protein kinase (PKA) (Knighton et 
al., 1991a; 1991b). PKA is a serine/threonine kinase, although subsequent structures 
demonstrate that all protein kinases possess a conserved core composing two lobes, a 
N-terminal small lobe (N-lobe) and a C-terminal large lobe (C-lobe). The N-lobe usually 
consists of five β-strands (β1-5) and one α-helix (αC). Also in the 1990s, structures of 
the insulin receptor kinase (IRK) in the inactive and active states were solved (Hubbard, 
1997; Hubbard et al., 1994). The IRK and PKA structures revealed that the inactive 
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structures are in an ‘open’ conformation where as the active kinase structures are in a 
‘closed’ conformation (Figure 1.2). The N-lobe has been shown to be quite dynamic, 
and movement of αC and the N-lobe towards the C-lobe is crucial for catalysis. Thus, the 
orientation of αC (cyan in Figures 1.2 and 1.3) with respect to the C-lobe can be 
indicative of an inactive (outward orientation of αC) or active (inward orientation of αC) 
structure. The predominately helical C-lobe is thought to be more rigid, and contains 
seven helixes (αD through αI) as well as four short β-strands (β6 through β9). Key 
features of an inactive and active kinase structure are shown for IRK in Figures 1.2 and 
1.3 and discussed in more detail below. 
Between the N-lobe and the C-lobe resides the substrate cleft, where ATP, divalent 
cations, and peptide substrate bind (Figure 1.2B and 1.3). The glycine rich phosphate 
binding loop (P-loop) between β1-2 in the N-lobe (orange in Figures 1.2 and 1.3) 
accommodates nucleotide binding and is able to make backbone interactions with ATP. 
The movements of αC mentioned above aid in ATP binding by promoting formation of a 
salt bridge (Figure 1.2B and 1.3B) between a glutamate acid in αC (Glu1047 in IRK) and 
a conserved lysine in β1 (Lys1030 in IRK), which is important in positioning the β1 lysine 
to interact with the α- and β- phosphates of ATP (Huse and Kuriyan, 2002; Jura et al., 
2011). Also essential for ATP binding is coordination of magnesium ions in the active 
site by a conserved aspartate residue (Asp1150 in IRK) of the DFG (Asp-Phe-Gly) motif 
within the activation loop in the C-lobe (Huse and Kuriyan, 2002). Peptide substrate 
binds in the cleft, with the tyrosine substrate directed towards ATP and another 
conserved aspartate residue in the C-lobe known as the catalytic base (Asp1132 in IRK). 
The N-lobe and the C-lobe are connected by the β5-αD loop, also known as the hinge 
region (black in Figures 1.2 and 1.3). Motion and dynamics in the hinge region have 
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been noted to be important for kinase activation (Hoofnagle et al., 2001; 2004; Lee et al., 
2005; Sours et al., 2014; Xiao et al., 2014). Accordingly, one mechanism of 
autoinhibition proposed for FGFR1 is a network of interactions at the hinge region that 
act as a “molecular brake” by holding the kinase in an inactive conformation (Chen et al., 
2007).  
A sequence insert (green in Figures 1.2 and 1.3) within the kinase domain also exists in 
RTKs to varying degrees, with some RTKs having no appreciable kinase insert domain 
(KID) and others having inserts of up to 100 amino acids (Locascio and Donoghue, 
2013; Ullrich and Schlessinger, 1990). Many of the KIDs are thought to be important 
sites of phosphorylation, since they often contain key tyrosines, serines, or threonines. 
However, there are several RTKs that have a recognizable short KID loop that do not 
contained a tyrosine, serine, or threonine and have been termed “non functional” KIDs 
(Locascio and Donoghue, 2013). The question remains whether the ~10-20 amino acid 
“non functional” KID loops have additional roles in these RTKs.  
Within the C-lobe is the activation loop (magenta in Figures 1.2 and 1.3), one of the 
most important regions of the kinase domain since it is known to influence both substrate 
binding and kinase activity (Kornev and Taylor, 2010). The activation loop is 20-35 
amino acids long, and is defined by the highly conserved DFG motif at the N-terminus 
and the APE (Ala-Pro-Glu) motif at the C-terminus (Nolen et al., 2004). As shown in 
Figure 1.2A, the activation loop of IRK is situated in the substrate cleft so that a key 
tyrosine (Tyr1162 in IRK) projects towards the catalytic base (Asp1132 in IRK ) in the 
inactive structure. However, phosphorylation of the activation loop causes a 
conformational change making the substrate-binding pockets available for substrate to 
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bind as shown in the active IRK structure in Figure 1.2B. (See below for more 
information regarding the autoregulation of TKDs.) 
Strikingly, crystal structures of all protein kinases solved in their active state share very 
similar characteristics and remarkably similar structures, whereas inactive (autoinhibited) 
kinases adopt an array of different configurations that seem to be family-specific (or 
receptor-specific); suggesting a wide diversity in autoinhibitory mechanisms (Huse and 
Kuriyan, 2002; Lemmon and Schlessinger, 2010). Indeed, the details of kinase 
autoinhibition have been shown to differ even within an RTK family where the kinase 
domains share 90% sequence identity (the FGFR family (Lew et al., 2007)). The 
mechanism of kinase autoinhibition remains unknown for the Trk receptors, and may 
differ between TrkA and TrkB, which share ~67% identity in the ICD and 88% in the TKD 
(Brodeur et al., 2009).   
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Figure 1.2. Inactive and active structures of the IRK TKD. (A) Inactive structure of the 
IRK TKD in cartoon representation with side chains of residues discussed in the text in 
stick representation. Notice that the activation loop (magenta) is located in the cleft 
between the N-lobe and C-lobe.  (B) Active structure of IRK TKD in the same orientation 
as the inactive structure in (A). Notice that the N-lobe rotates towards the C-lobe in the 
active structure compared to the inactive structure. The activation loop in the IRK active 
structure is phosphorylated and no longer obstructs the substrate binding pockets. The 
following are colored for clarity: P-loop (orange), αC (cyan), hinge (black), KID (green), 
and activation loop (magenta). 
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Figure 1.3. Substrate binding pockets.  (A) ATP, Mg2+ and peptide substrate bind in a 
cleft between the N-lobe and C-lobe of the IRK TKD (shown in surface representation 
with specific features colored as in Figure 1.2).  (B) Amino acids essential for catalysis 
include Asp1150 (part of the Asp-Phe-Gly motif) which coordinates the magnesium ions in 
the active site and Asp1132, the catalytic base. Also shown is the Glu1047-Lys1030 salt-
bridge, which orients Lys1030 for coordination of ATP.  
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1.5. Autoregulatory mechanisms in RTK TKDs. 
	  
As mention previously, crystal structures of the insulin receptor TKD in its inactive 
conformation show how an activation loop tyrosine (Tyr1162) projects into the active site, 
preventing binding of substrate and restraining the rest of the loop to block ATP binding 
(Figure 1.4, ‘Inactive A’: activation loop = black line). Upon extracellular ligand binding, 
tyrosines in the activation loop become autophosphorylated in trans, causing a 
conformational change that allows substrate and ATP to bind the kinase, with the 
activation loop “relaxing” into a configuration that aids catalysis (Figure 1.4, ‘Active’) 
(Blume-Jensen and Hunter, 2001; Hubbard, 2004). The Trk receptors also have 
tyrosines in their activation loop, in a YxxxYY motif similar to that seen in IRK, which 
have been shown to be autophosphorylated upon TrkA and TrkB activation in cells 
(Cunningham et al., 1997; Guiton et al., 1995; 1994). 
Biochemical, mutational, and crystallographic studies of several RTKs (EphB, Flt3, and 
MuSK) have demonstrated that the intracellular JM region can alternatively autoinhibit 
the kinase domain (Griffith et al., 2004; Till et al., 2002; Wybenga-Groot et al., 2001). 
The precise mode of this autoinhibition is RTK-specific, but generally involves the JM 
region making contacts with the kinase domain that stabilizes the inactive conformation 
(Figure 1.4, ‘Inactive B’: JM = red line). In these cases, autophosphorylation of tyrosines 
in the JM region releases the inhibitory effect. There is one tyrosine in the JM region of 
both TrkA (Y490 in isoform Ι, or Y496 in isoform ΙΙ) and TrkB (Y516), within an NPxY 
motif. Several other RTKs (insulin receptor, and FGFR1) employ JM-mediated 
autoregulatory mechanisms that do not require phosphorylation of the JM region for 
reversal. Specific residues within the JM region are crucial for correctly stabilizing 
structural elements within the kinase domain (insulin receptor), or are important for 
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defining optimal interactions between juxtaposed kinase domains in the activated dimer 
(FGFR1) (Bae et al., 2010; Hubbard, 2004). In the case of TrkA and TrkC, mutation of 
the single JM tyrosine to phenylalanine had little effect on autophosphorylation in cell 
based studies (Obermeier et al., 1994; Stephens et al., 1994). However, mutation of the 
corresponding JM tyrosine to phenylalanine in TrkB did diminish autophosphorylation in 
cell based assays (Minichiello et al., 1998; Postigo et al., 2002). Interestingly, recent 
work in the Lemmon laboratory determined that the JM region of EGFR serves as a 
kinase-activating (rather than autoinhibitory) element (Hubbard, 2009; Jura et al., 2009; 
Red Brewer et al., 2009; Thiel and Carpenter, 2007), underscoring the importance of 
understanding the function of this region in all RTKs. 
Additional autoregulatory mechanisms have been shown that involve the C-tail of the 
RTK blocking its active site, as demonstrated for the Tie2 receptor and suggested for 
EGFR (Figure 1.4, ‘Inactive C’: C-tail = green line). Both Tie2 and EGFR have relatively 
long C-tails, whereas the C-tail in the Trk receptors is quite short (just 15 residues). 
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Figure 1.4. Autoregulatory mechanisms of kinase domains. Various kinase inactive 
configurations are compared to the active form. The mechanisms for autoinhibition can 
involve the activation loop (A), JM (B) and C-tail (C). Black line = activation loop. Red 
line = JM. Green line= C-tail.  
 
 
1.6. The Trk TKDs are part of the IRK TKD superfamily 
	  
A classic paper by Hanks et al. in 1988 was the first of its kind to classify all the known 
protein kinases into families according to primary sequence as well as identify many of 
the conserved features of a kinase domain. That study identified a subset of RTKs that 
have similar TKDs and, in particular, a unique motif in their activation loops. This subset 
of RTKs is known as the IRK TKD family (Hanks et al., 1988). Since the study by Hanks 
et al. additional kinases have been discovered that contain this motif and have been 
included in the IRK TKD family (Morris et al., 1994). An alignment of members of the IRK 
TKD family (Figure 1.5A) demonstrates that all members possess a YxxxYY motif in 
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their activation loop. As a comparison, Figure 1.5B shows an alignment of IRK with 
EGFR and FGFR1, RTKs that do not have the YxxxYY motif.  As mentioned above, the 
activation loop of IRK acts almost like a pseudosubstrate, with the middle tyrosine of the 
YxxxYY binding as if it were a substrate (Hubbard et al., 1994). Once the tyrosines of the 
YxxxYY motif become autophosphorylated, the activation loop drastically changes 
conformation, allowing ATP and peptide substrate access to the substrate binding 
pockets (Hubbard, 1997). Since all the other members of the IRK TKD family contain the 
YxxxYY motif, all members were considered likely to utilize the same mechanism of 
autoinhibition and activation. 
Earlier crystal structures of the IGF1R and MuSK TKDs agreed with the hypothesis that 
RTKs with the YxxxYY motif all have a similar activation loop conformation in the 
inactive structure – further suggesting these RTKs all have the same autoinhibition 
mechanism as IRK. However, subsequent structures of the inactive TKDs of Met and Alk 
surprisingly revealed quite distinct activation loop conformations, challenging the 
hypothesis that all IRK family members are regulated the same way. High resolution 
structures of a certain IRK TKD family members, notably from the Trk, Ror, and DDR 
families, were notably absent from the protein data bank (PDB). A thorough examination 
of all the inactive TKDs from IRK family members will help elucidate the mechanism of 
autoregulation within this family as well as aiding interpretation of TKD mutations of IRK 
TKD family members. 
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Figure 1.5. Alignment of IRK family TKDs. (A) Activation loop sequences from an 
alignment of IRK TKD family members. (B) As a comparison, activation loop sequences 
from an alignment with IRK, TrkA, EGFR, and FGFR. 
 
 
1.7. RTK signaling specificity 
	  
Once activated by extracellular ligand, the TKDs of RTKs trans-autophosphorylate 
tyrosines in the ICD further, both enhancing catalytic activity and creating 
phosphotyrosine binding sites for SH2 and PTB domains in docking molecules and 
downstream effectors (Figure 1.6). Docking molecules (e.g. Shc and FRS2) interact via 
additional adapter proteins (such as Grb2 and Crk) with GTPase exchange factors 
(GEFs) that activate small GTPases such as Ras (via Sos) and Rap1 (via C3G). The 
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activation of these small GTPases in turn activates B-Raf or C-Raf to promote signaling 
through the MAPK pathway (Lemmon and Schlessinger, 2010) (Figure 1.6). The 
resulting activation of Erk leads to transcription factor activation, gene expression and 
cellular responses (Murphy and Blenis, 2006) (Figure 1.6). This highly simplified linear 
description of RTK signaling is shared by many of the RTKs, even though the cellular 
fates upon receptor activation are quite varied. 
In the past 20 years, RTK signaling has been well studied using rat pheochromocytoma 
(PC12) cells. Important early experiments analyzed signaling differences between 
activated TrkA and EGFR in these cells. Despite engaging similar complements of 
downstream signaling molecules, TrkA activation leads to PC12 cell differentiation, 
whereas EGFR activation leads to cell proliferation (Marshall, 1995). These classic 
experiments revealed that NGF-induced TrkA activation produces sustained Erk 
activation in PC12 cells, whereas EGFR activation promotes only transient Erk 
activation. It is now quite well established that the duration of Erk activation following a 
signal determines the effect of that signal on cellular fate (i.e. differentiation vs. 
proliferation) (Murphy and Blenis, 2006). One way in which the different time courses of 
Erk activation are ‘interpreted’ to achieve this involves phosphorylation-dependent 
regulation of immediate early gene product stability (Murphy and Blenis, 2006; Murphy et 
al., 2004). Both transient and sustained Erk activation leads to induction of immediate 
early genes (IEG). Several IEG products, such as c-Fos, are quite unstable, but are 
stabilized by Erk phosphorylation. If Erk activation is transient, the lifetime of the IEG 
products is very short. However, when (and only when) Erk activation is sustained, Erk 
phosphorylates and stabilizes IEG products such as c-Fos, allowing them to induce 
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expression of ‘late response’ genes involved in differentiation (Murphy and Blenis, 2006; 
Murphy et al., 2004). 
The origin of the differences in time course of Erk activation remains quite unclear, 
however. Over the years, studies have variously implicated differences in receptor 
internalization, receptor levels, receptor localization, differential use of small GTPases, 
and engagement of distinct feedback loops to explain how TrkA and EGFR signaling 
cause differentiation and proliferation respectively in PC12 cells (Murphy and Blenis, 
2006). 
Earlier studies comparing signaling by TrkA and EGFR in PC12 cells identified key 
network properties that may explain the sustained and transient modes of Erk activation 
respectively. York et al. (York et al., 1998) reported that, whereas Erk activation by 
EGFR signaling occurs largely through the Grb2/Sos/Ras pathway, TrkA signaling also 
engages the FRS2/Crk/C3G/Rap1 pathway. A key difference between these pathways is 
that the Grb2/Sos/Ras pathway contains several negative feedback loops, including 
receptor activation of Ras-GAP and inhibitory Erk phosphorylation of Sos (Lemmon and 
Schlessinger, 2010). By contrast, Rap1’s GAP is not activated by RTKs, and the C3G 
Rap1 exchanger is not subject to negative feedback. Negative feedback is likely to 
cause EGFR-induced Erk activation to be transient, and the relative lack of this feedback 
in TrkA signaling via Rap1 allows a more sustained response. Another study suggested 
that formation of a long-lived complex between TrkA and the FRS2 docking protein may 
increase the longevity of its signaling to Erk, and thus more sustained Erk activation 
(Kao et al., 2001). 
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Additional modulation of the network is achieved by the underappreciated role of protein 
phosphatases. Recent studies have revealed that the phospho-turnover of RTKs at the 
cell surface is very rapid. This suggests that the activity of RTKs has to exceed a 
threshold controlled in part by surrounding phosphatase activity to increase levels of 
autophosphorylation (Kleiman et al., 2011).  
Interestingly, overexpression of EGFR or IRK converts the cellular proliferation response 
normally observed for EGFR and IRK activation in PC12 cells into cellular differentiation. 
These studies reveal that the strength per se of the initiating signal can be a determinant 
of downstream signaling and cellular response (Dikic et al., 1994; Traverse et al., 1994). 
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Figure 1.6. Simple schematic of RTK signaling. Growth factor binding to its receptor 
induces dimerization and activation of the TKD.  Autophosphorylation by the TKD 
creates docking motifs for adapter molecules (green). These molecules interact with 
GEFs (grey) that activate small GTPases (purple) that in turn activate the MAPK 
pathway (yellow).   The MAPK pathway consists of Raf, Mek and Erk. Activation of Erk 
leads to activation of transcription factors that elicit cellular responses. 
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1.8. RTKs in disease 
	  
The important role of RTKs in initiating cellular signaling and dictating cellular response 
is evident by the prevalence of aberrant activity of RTKs in various diseases and in 
particular cancer. In fact, many RTKs were originally identified as agents promoting 
tumorigenesis. For example, in the 1980s viral oncogenes from the simian sarcoma virus 
and avian erythroblastosis virus respectively were determined to transform cells through 
autocrine activation of PDGFR (by expressing its ligand) and constitutively signaling by 
an activated EGFR variant (Lemmon and Schlessinger, 2010). Furthermore, several 
RTKs were initially identified when parts of their coding sequence was found in aberrant 
soluble fusion proteins that promote tumorigenesis. The Trk (tropomyosin related kinase) 
receptors were first identified from the trk oncogene in colon cancer, which encodes an 
oncogenic fusion protein created by chromosomal rearrangement that juxtaposes the 
coding region for the TrkA TKD with non-muscle tropomyosin, creating a constitutively 
active tropomyosin/TrkA TKD fusion oncoprotein (Greco et al., 2010). These discoveries 
highlight some of the mechanisms of RTK dysfunction in cancers. In the case of human 
cancer, aberrant RTK activation can occur by chromosomal translocation (as with trks), 
autocrine activation, overexpression, or gain-of-function mutations (Casaletto and 
McClatchey, 2012; Lemmon and Schlessinger, 2010). 
Recent increased sequencing efforts have lead to abundance of data regarding TKD 
mutations of RTKs in cancer. Interpreting the significance of these mutations remains a 
challenge, since it is increasingly evident that many mutations revealed by sequencing 
are “passenger” mutations rather than the “driver” mutations that are actually promoting 
cell proliferation and tumorigenesis (Dancey et al., 2012). Structural studies have been 
instrumental in understanding the consequences of mutations.  
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There are various reports of TKD mutations activating the TKD by disturbing 
autoinhibitory mechanisms that normally keep the TKD inactive until ligand binds and 
induces activation. For example, structural studies of the intracellular domain of the stem 
cell factor receptor (KIT) elucidated the autoinhibitory mechanisms utilized by WT KIT 
and demonstrated that cancer mutations disturb these autoinhibitory mechanisms 
(Corless and Heinrich, 2008; Lemmon and Schlessinger, 2010). Mutations in the EGFR 
TKD identified in non-small-cell lung cancer (NSCLC) have also been shown by 
structural and biochemical studies to release the EGFR TKD from the autoinhibitory 
mechanisms that normally hold the WT EGFR TKD in an inactive state (Choi et al., 
2006; Zhang et al., 2006). Thus, understanding the mechanism of autoregulation of 
TKDs is vital for understanding the consequences of TKD mutations. 
However, not all RTKs have been as thoroughly studied structurally and biochemically 
as KIT and EGFR. For example, the mechanism of autoinhibition for the Trk family was 
not clearly known at the time of starting this thesis, because there were no kinase 
domain structures available for any member of the Trk family. The mechanism of TKD 
activation in the case of oncogenic TrkA TKD-containing fusion proteins is thought to 
involve dimerization mediated by the fusion partner, which frequently contains coiled-
coiled domains (Greco et al., 2010). However, if and how mutations activate Trk family 
members in the intact RTK context is not known. There are reports of mutations of Trk 
family members in acute myeloid leukemia (Tomasson et al., 2008), colorectal (Bardelli 
et al., 2003), lung (Davies et al., 2005; Ding et al., 2008; Marchetti et al., 2008), and 
breast cancers (Stephens et al., 2005) but without structural and biochemical analysis 
the consequences of these mutations are difficult to predict. Prior to this study, 
interpretation of some of these mutations was based on homology models of other RTKs 
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(Tomasson et al., 2008). However, previous reports suggested that at least TrkA has a 
unique autoinhibitory mechanisms – based on the observation that activating mutations 
of conserved residues in Met and Kit have a distinct effect in TrkA and in one case 
abrogates kinase activity of TrkA (Miranda et al., 2002). Thus, interpretation of the 
mutations of Trk family members in cancer has proven to be challenging since it was not 
yet known if these mutations were “passengers” or “driver” mutations. Along with 
mutations of Trk family members in certain cancers, there are other reports that have 
identified TrkA loss-of-function mutations in congenital insensitivity to pain with 
anhidrosis (Indo, 2001). 
The Trk family has also been implicated in neuroblastoma, a cancer of the sympathetic 
nervous system and one of most common pediatric neoplasms (Brodeur et al., 2009). 
The clinical outcomes of neuroblastoma vary greatly, ranging from benign cases that 
spontaneously regress to malignant cases leading to fatality. Unfortunately, the majority 
of cases that occur in children older than one year are malignant with long-term survival 
less than 40% (Brodeur, 2003; Brodeur et al., 2009; Maris et al., 2007). The 
heterogeneous nature of neuroblastoma is an intriguing biological and clinical dilemma. 
An interesting correlation is that tumor characteristics are closely related to the 
expression of TrkA and TrkB. Studies have shown that expression of TrkA occurs in 
biologically favorable neuroblastomas, whereas expression of TrkB occurs in biologically 
unfavorable neuroblastomas (Brodeur et al., 1997; 2009). At the start of this study there 
was no evidence of mutations of TrkA or TrkB in neuroblastoma, but sequencing efforts 
were just starting to increasingly look at the TKDs of TrkA and TrkB. 
Structural and biochemical studies not only provide insight into the consequences of 
certain mutations, but also provide a framework to therapeutically target the TKDs that 
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promote turmorigenesis. A thorough understanding of the autoregulatory mechanisms of 
TKDs is crucial for effective therapies. This requirement was clearly illustrated in recent 
studies with B-Raf inhibitors, underscoring the consequences of not fully understanding 
the activation mechanism of a kinase and the organization of the network in which it is 
embedded. Although certain B-Raf inhibitors have proven very successful in treating 
some melanomas (driven by mutated B-Raf), the very same inhibitors can actually 
increase cell proliferation by driving the MAPK pathway in other cellular contexts 
(Cichowski and Janne, 2010). 
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Chapter 2:  
Assessing the range of kinase autoinhibition mechanisms in the insulin 
receptor family 
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2.1.  Introduction 
	  
Recent clinical success with targeted inhibitors of the EGFR, B-Raf, and ALK kinases 
underscore both the promise and the challenges of ‘personalized’ cancer medicine 
(Dancey et al., 2012; Yauch and Settleman, 2012).  Well-defined activating mutations in 
each of these kinases have been identified as oncogenic “drivers”, promoting 
uncontrolled proliferative or cell survival signaling that can be curbed with specific kinase 
inhibitors.  As genomic analysis of tumors burgeons, however, it is becoming 
increasingly clear that many mutations found in cancer are “passengers” rather than 
drivers (Dancey et al., 2012).  The ability to determine which mutations in a tumor are 
oncogenic drivers – and thus which signaling nodes should be targeted therapeutically – 
will be crucial for advancing personalized medicine in oncology. 
For protein kinases – including receptor tyrosine kinases (RTKs), which are frequently 
found as oncogenic drivers in cancer (Lemmon and Schlessinger, 2010) – a key goal is 
to understand which mutations increase constitutive kinase activity and signaling.  The 
EGF receptor provides an excellent illustration of how structural understanding of kinase 
activation mechanisms (Zhang et al., 2006) can explain driver mutations in non-small 
cell lung cancer (NSCLC) (Sharma et al., 2007).  The inactive EGFR TKD is 
autoinhibited by intramolecular interactions between a short α-helix in its activation loop 
and another important helix (αC) that is consequently displaced from the position it 
adopts in the active kinase.  This mode of autoinhibition closely resembles that seen in 
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Src family and cyclin-dependent kinases (CDKs) (Jura et al., 2011).  Known driver 
mutations activate EGFR by destabilizing these intramolecular autoinhibitory 
interactions.  Intriguingly, oncogenic driver mutations that destabilize very similar 
autoinhibitory interactions are also found in ALK (anaplastic lymphoma kinase) (Bossi et 
al., 2010; Bresler et al., 2011; Lee et al., 2010), a member of the large insulin receptor 
kinase (IRK) subfamily of RTKs (Manning et al., 2002; Morris et al., 1994) that is 
important in neuroblastoma (Carpenter and Mossé, 2012).  Despite the fact that the ALK 
TKD shows closest sequence similarity to IRK family members, the autoinhibitory 
interactions that define its inactive conformation most closely resemble those in EGFR, 
Src and CDKs (Hubbard et al., 1994; Jura et al., 2011).  As in EGFR, ALK TKD 
structures reveal hydrophobic interactions between a small α-helix in the activation loop 
and the crucial αC helix that stabilize the inactive kinase conformation (Bossi et al., 
2010; Lee et al., 2010).  The side-chains of the ALK residues most frequently mutated in 
neuroblastoma (Carpenter and Mossé, 2012) (Phe1174 and Arg1275) make important 
contributions to these autoinhibitory interactions, and their mutation causes constitutive 
ALK activation.  Indeed, Phe1174 and Arg1275 in ALK are structurally equivalent to EGFR 
residues Val769 and Leu861 (Bresler et al., 2011), at which activating mutations are also 
seen in NSCLC (Sharma et al., 2007). 
Structural studies have revealed a spectrum of autoinhibitory mechanisms for IRK family 
RTKs.  ALK lies at one extreme, with an EGFR/Src/CDK-like mode of autoinhibition.  
IRK lies at the other, with a very different autoinhibitory activation loop conformation that 
simultaneously occludes the ATP-binding site and projects a key tyrosine side-chain 
(Tyr1162) into the substrate-binding site (Hubbard et al., 1994). The autoinhibitory 
mechanisms of inactive IGF1R (Munshi et al., 2002) and MuSK (Till et al., 2002) kinases 
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closely resemble that seen in IRK, with very similar activation loop configurations.  
However, structures of the inactive TKDs of the IRK family members Met (Wang et al., 
2006) and Ron (Wang et al., 2010) have quite distinct activation loop conformations.  
Since mutations that disrupt autoinhibitory interactions are known to be important 
oncogenic drivers in ALK (and Met), it seems clear that understanding the mechanism of 
TKD autoinhibition will be important for predicting which mutations are likely to be 
significant for IRK family RTKs in cancer or other diseases in which RTK activation is 
important.  Since the cases of Met, ALK, and Ron demonstrate that not all IRK family 
RTKs are regulated in the same way as IRK, we were motivated to ask how other 
kinases in this family are regulated.  Notably absent from the list of IRK-family TKDs with 
known structure are members of the Trk, Ror, and DDR subfamilies, which have all been 
implicated in cancer (Brodeur et al., 2009; Hammerman et al., 2011; Rebagay et al., 
2012) and other diseases.  Here, we describe crystal structures to 2.4Å resolution of the 
inactive TKDs from TrkA (a receptor for nerve growth factor (Huang and Reichardt, 
2003)) and Ror2 (now known to be a Wnt receptor (Green et al., 2008)).  In the context 
of the other IRK family structures, these new results provide a useful framework for 
interpreting the consequences of TKD mutations in this family. 
 
2.2.  Overview of TrkA and Ror2 Structures 
	  
Both the TrkA and Ror2 TKD structures were solved in their unphosphorylated inactive 
forms (Figure 2.1), with no bound nucleotide. Data collection and refinement statistics 
are shown in Table 2.1.  The TrkA and Ror2 structures exhibit the common kinase 
topology consisting of an N-terminal lobe and a larger C-terminal lobe. The N-terminal 
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lobe consists of a twisted five-stranded β-sheet plus one conserved α-helix, called αC, 
that plays a key role in the transition from an inactive to an active conformation (Huse 
and Kuriyan, 2002).  The larger C-terminal lobe is predominantly helical, and also 
contains the activation loop that undergoes key conformational changes upon activation 
– contributing to the catalytic and substrate binding sites in the active conformation of 
the TKD, but instead playing an autoinhibitory role in the inactive conformation. 
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Figure 2.1.  Structures of TrkA and Ror2 TKDs 
Structures of inactive TKDs from TrkA (left) and Ror2 (right) in cartoon representation.  
The amino- and carboxy-terminal lobes (N-lobe and C-lobe) are labeled, as is the 
catalytically important αC helix.  The activation loops are labeled and highlighted in cyan 
(TrkA) and magenta (Ror2).  Side-chains in the DFG motif of TrkA (Asp668, Phe669, 
Gly670) and the equivalently located DLG motif in Ror2 (Asp633, Leu634, Gly635) are shown, 
and tyrosines from the YxxxYY motif are shown in stick representation.  Also shown is 
the invariant lysine in strand β3 (Lys544 in TrkA, Lys507 in Ror2), which forms a salt bridge 
with αC Glu524 in Ror2 (but not TrkA).  The catalytic base aspartate (Asp650 in TrkA, 
Asp615 in Ror2) is also shown and labeled.  Molecule A was used for Ror2-TKD.  The N- 
and C-terminal residues of the modeled structure are marked where visible in the 
orientation shown. (Ror2 TKD was crystallized and the structure solved by J.M.) 
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Table 2.1.  Data collection and refinement statistics (molecular replacement) 
Each dataset was collected from a single crystal. Values for the highest-resolution shell 
are shown in parentheses. (Ror2 TKD was crystalized and the structure solved by J.M.) 
   
 TrkA Ror2 
   
Data collection   
  Space group H32 C2221 
  Cell dimensions   
      a, b, c (Å) 105.0, 105.0, 203.3 102.8, 112.9, 114.8 
      α, β, γ  (°)  90, 90, 120 90, 90, 90 
  Resolution (Å) 50.0-2.4 46.9-2.4 
  Rsym 0.065 (0.553) 0.112 (0.565) 
  I/σ 52.9 (5.3) 21.9 (4.1) 
  Completeness (%) 99.9 (100) 100 (99.9) 
  Redundancy 11.1 (11.3) 7.5 (7.3) 
Refinement   
  Resolution (Å) 2.4 2.4 
  No. reflections 17195 26251 
  Rwork / Rfree 0.20/0.25 0.17/0.20 
  No. atoms   
      Protein 2261 4274 
      Ion 0 16 (4 x NO3-) 
      Water 77 228 
  B-factors   
      Protein 76.3 39.1 
      Ion  49.6 
      Water 62.6 38.3 
  R.m.s. deviations   
      Bond lengths (Å) 0.004 0.003 
      Bond angles (°) 0.758 0.643 
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2.3.  Autoinhibition of TrkA and Ror2 TKDs 
	  
Both the TrkA and Ror2 TKDs share one of the key autoinhibitory features of IRK 
(Hubbard et al., 1994), projecting the second tyrosine of the YxxxYY (Tyr-Xaa-Xaa-Xaa-
Tyr-Tyr motif found in the activation loop of IRK family kinases into the (tyrosine) 
substrate binding site.  As shown in Figure 2.2A, tyrosines Tyr680 of TrkA and Tyr645 of 
Ror2 occupy the same position as Tyr1162 in IRK (Hubbard et al., 1994) (marked with an 
asterisk in Figure 2.2A), and make similar interactions with both the catalytic base 
aspartate (Asp650 and Asp615 in TrkA and Ror2 respectively, Asp1132 in IRK) and an 
arginine conserved in IRK family kinases (Arg654 and Arg619 in TrkA and Ror2 
respectively, Arg1136 in IRK).  The activation loop conformations of the TrkA and Ror2 
TKDs are very similar to those seen in IRK, MuSK, and IGF1R (Hubbard et al., 1994; 
Munshi et al., 2002; Till et al., 2002) (Figure 2.2A), whereas the ALK, Met, and Ron 
activation loops are quite different (Figure 2.2B), as discussed below. 
The TrkA and Ror2 TKDs in their inactive conformations also mirror other key aspects of 
the autoinhibitory mechanisms originally described for IRK (Hubbard et al., 1994) – 
although Ror2 has several unique features that suggest a slightly different mode of 
autoinhibition.  The activation loop conformation in both the TrkA and Ror2 TKDs is such 
that it directly occludes the space in which the phosphate moieties of ATP would bind to 
an active kinase – as previously described for inactive IRK, MuSK, and IGF1R (Hubbard 
et al., 1994; Munshi et al., 2002; Till et al., 2002).  As shown in Figure 2.3, backbone 
and/or side-chain atoms in the region following the DFG (Asp-Phe-Gly) motif occlude the 
phosphate-binding site, as seen in particular for Met671 and Ser672 of TrkA and Leu636 of 
Ror2.  A switch from this so-called “DFG-out” (inactive) conformation seen in TrkA, Ror2 
and inactive IRK to an “DFG-in” (active) configuration reverses this inhibition in the 
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active IRK structure, as seen at the left of Figure 2.3.  Like IRK, inactive TrkA also 
places the side-chain of its DFG motif phenylalanine (Phe669) into the binding site for the 
adenine ring to further block ATP binding.  This feature is common to IRK (Phe1151), 
MuSK, and IGF1R.  However, Ror2 does not mimic this aspect of the autoinhibitory 
interactions – and has the Phe of its Asp-Phe-Gly motif replaced with a leucine.  The 
unusual DLG (Asp-Leu-Gly) motif in Ror2 adopts an “DFG-out”-like conformation 
(Figures 2.1 and 2.3), but it is displaced approximately 4-4.5Å away from the ATP-
binding site compared with that in IRK and TrkA, and therefore does not impact the 
location adopted by the adenine ring in active kinases.  Instead, the side-chain of Tyr555, 
two positions from the gatekeeper residue (Phe553) at the end of strand β5 (and quite 
distant from the Asp-Phe-Gly motif), occupies an unusual position for inactive kinases, 
and occludes the predicted binding site for the ATP adenine ring (Figure 2.3).  The 
corresponding residue is a tyrosine in numerous other TKDs, although it is replaced by 
phenylalanine or leucine in others.  Regardless of the residue identity, however, the 
side-chain orientation in all other inactive IR family TKDs, as well as EGFR, FGFRs, and 
Src family TKDs is orthogonal to that of Tyr555 in Ror2, suggesting that the ability of this 
tyrosine to occlude the ATP binding site may be a feature unique to Ror2.  It will be 
interesting to determine whether Tyr555 is a phosphorylation site in Ror2, and whether 
phosphorylation (or mutation) of this residue enhances kinase activity. 
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Figure 2.2.  Comparison of activation loop configurations in IRK family kinases 
Known inactive conformation structures of IRK family kinases (in addition to TrkA and 
Ror2) were overlaid on that of the insulin receptor (PDB 1IRK (Hubbard et al., 1994): 
grey – with the TKD shown in surface representation), and their activation loops colored.  
(A) The activation loops of MuSK (PDB 1LUF (Till et al., 2002): orange), TrkA (cyan), 
Ror2 molecule A (magenta) and IGF1R (PDB 1M7N (Munshi et al., 2002): yellow) align 
well with that of IRK.  (B) The activation loops of Ron (PDB 3PLS (Wang et al., 2010): 
red), Met (PDB 2G15 (Wang et al., 2006): blue), and ALK (PDB 3L9P (Lee et al., 2010): 
green) are more widely variable and are compared with that of IRK (grey).  Tyrosine 
side-chains in the YxxxYY motif are shown, and the substrate-mimicking tyrosine (Tyr1162 
in IRK) is marked with a red asterisk. 
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Figure 2.3.  ATP binding-site occlusion by the activation loop in inactive IRK, 
TrkA, and Ror2 TKDs 
Structures of the inactive TKDs from IRK (Hubbard et al., 1994), TrkA, and Ror2 were 
overlaid on the structure of active IRK (PDB 1IR3) determined with bound peptide 
substrate and a non-hydrolyzable ATP analog, adenylyl imidodiphosphate (AMP-PNP) 
(Hubbard, 1997).  Close-up views of residues surrounding the binding site for AMP-PNP 
(shown from the 1IR3 structure) are shown for inactive IRK (activation loop colored 
grey), TrkA (activation loop colored cyan), and Ror2 (activation loop colored magenta).  
Whereas the 1IR3 (active) structure readily accommodates AMP-PNP, the nucleotide 
binding site is directly occluded by the activation loop in inactive IRK, TrkA, and Ror2 – 
with backbone and side-chain clashes with the phosphate groups.  In addition, the Asp-
Phe-Gly motif phenylalanine (Phe1151 in IRK and Phe669 in TrkA) blocks the binding site 
for the adenine ring of AMP-PNP.  This inhibitory interaction is not maintained in Ror2, 
which has a Phe-to-Leu substitution in the DFG motif (yielding DLG), and Tyr555 from 
elsewhere in the TKD takes on a similar role. 
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2.4.  Comparison with ALK, Met, Ron, and IRK autoinhibition 
	  
In contrast with the TKDs depicted in Figure 2.2A, the activation loops of inactive ALK, 
Met, and Ron do not interfere directly with ATP binding, and adopt a diverse array of 
conformations (Figure 2B).  Tyrosines in the YxxxYY motif of ALK and Met do not project 
into the substrate binding site in the manner described above for TrkA, Ror2, and IRK.  
In Ron, Tyr1238 does occupy the substrate tyrosine site, but approaches from quite a 
different orientation than is seen in IRK and the other TKDs shown in Figure 2.2.  
Autoinhibition of ALK, Met, and Ron instead relies substantially on direct interactions 
between the activation loop and the αC helix – both displacing the αC helix from the 
position it adopts in active kinases and distorting the activation loop.  This mode of 
autoinhibition is not employed by IRK (Hubbard et al., 1994) and is also not seen for 
MuSK or TrkA.  Ror2 lies between these two scenarios.  In addition to occluding the 
ATP-binding site like IRK, the Ror2 TKD activation loop also directly contacts the αC 
helix (Figure 2.4).  It does so through predicted hydrogen bonds between Asp633 from 
the DLG motif and a αC arginine side-chain (Arg528), made possible because of the 4-
4.5Å displaced position of this motif away from the active site in Ror2.  It is interesting 
that the αC helix is displaced further from the position adopted in active kinases in the 
case of inactive Ror2 than in the TrkA, IRK, MuSK, or IGF1R counterparts, and is closer 
to the position for the αC helix seen in Met and Ron.  Thus, Ror2 appears to employ a 
“hybrid” mode of autoinhibition that involves both direct occlusion of the ATP-binding site 
and activation loop/αC interactions.  By contrast, TrkA very closely resembles IRK. 
The different modes of IRK family kinase autoinhibition are also reflected in their normal 
(ligand-dependent) activation mechanisms.  The TKDs in Figure 2.2A resemble IRK, 
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with the initial activating event likely to be autophosphorylation of the tyrosine side-chain 
projecting into the substrate-binding site (Tyr680 in TrkA, Tyr645 in Ror2, Tyr1162 in IRK, 
Tyr1135 in IGF1R, and Tyr754 in MuSK) – thus reversing autoinhibition (Hubbard et al., 
1994; Till et al., 2002).  Phosphorylation of other tyrosines in the characteristic activation 
loop YxxxYY motif in these kinases disrupts additional autoinhibitory interactions (mostly 
with C-lobe residues) and/or stabilizes the active conformation.  The TKDs depicted in 
Figure 2.2B vary.  Since Ron places the side-chain of Tyr1238 from its activation loop in 
the substrate-binding site to inhibit the kinase, autophosphorylation of this tyrosine is 
likely to play a key role in receptor activation (Wang et al., 2010).  In both ALK and Met, 
YxxxYY motif tyrosines instead stabilize autoinhibitory activation loop/αC interactions in 
the inactive state, without directly impacting the substrate-binding site.  In Met, the 
Tyr1234 side-chain (equivalent to IRK Tyr1162) directly contacts αC, and its 
phosphorylation is required for Met activation (Wang et al., 2006).  Similarly, Tyr1278 in 
ALK (the first tyrosine in the YxxxYY motif) contributes directly to autoinhibitory 
activation loop/αC interactions, and its phosphorylation has been reported to be the 
initial event in ALK activation (Tartari et al., 2008). 
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Figure 2.4.  DFG motif conformation and activation loop/αC interactions in TrkA 
and Ror2 TKDs 
Left:  Close-up of the DFG motif region in TrkA-TKD, with the DFG motif itself colored 
cyan.  Note the absence of salt-bridge between the β3 invariant lysine (Lys544) and αC 
glutamate (Glu560) – for which complete side-chain density was not seen.  Van der 
Waal’s contacts between the Phe589 and Leu564 side-chains are likely to contribute to 
stabilization of the αC position. 
Right:  Close-up of the DFG motif equivalent in Ror2-TKD (colored magenta), which has 
the sequence DLG – with Leu634 replacing the normal phenylalanine at this position in 
other kinases.  Note that the β3 invariant lysine (Lys507) forms a salt-bridge with the αC 
helix glutamate (Glu524) even in the inactive Ror2 kinase (as also seen in ALK and Met), 
although the displaced αC helix position prevents Lys507 from contributing to an active-
like ATP-binding site.  The DLG motif of Ror2-TKD in the activation loop also interacts 
directly with the αC helix, thus stabilizing the inactive state through a mode that more 
closely resemble autoinhibition in Met, ALK, or EGFR.  Arg528 in the αC helix interacts 
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directly with both backbone and side-chain of Asp633 in the DLG motif to stabilize this 
conformation.  Mutations at Arg528 might be predicted to activate Ror2. 
 
2.5.  Possible relevance of TrkA and Ror2 TKD dimers 
	  
RTKs are well known to signal as dimers, with extracellular ligand binding inducing either 
dimerization or the transition from an inactive dimeric form to an active dimer (Lemmon 
and Schlessinger, 2010).  Accordingly, functional significance has been attached to 
dimers of both active and inactive TKDs.  Since the Ror2 TKD crystallized with two 
molecules in the asymmetric unit, we were therefore interested to ask whether any Ror2 
or TrkA TKD dimer – non-crystallographic or crystallographic – might be functionally 
relevant, perhaps as an ‘inactive dimer’ of the sort suggested for a symmetric EGFR 
TKD structure (Jura et al., 2009).  During the course of this work, other structures of Trk 
receptor kinases (Albaugh et al., 2012; Bertrand et al., 2012; Wang et al., 2012) and 
Ror2 were published or released in the Protein Data Bank (PDB).  It was therefore 
important to determine whether these other structures share any crystal packing modes 
with the TrkA and Ror2 structures described in the present paper. 
The unpublished Ror2 (PDB entry 3ZZW) contains two molecules in the asymmetric unit, 
in common with our structure.  In both cases, the two Ror2 TKD molecules form an 
antiparallel dimer, burying a total surface area of 1,725Å2 (our structure) and 2,640Å2 
(3ZZW) on the two TKDs.  However, the surfaces involved in each interface are quite 
different.  Within the Ror2 monomer, all of the structural features described here are 
maintained in 3ZZW, with the exception that molecule B in 3ZZW has a different DLG 
motif configuration and position – slightly closer to the “DFG out” conformation seen in 
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inactive IRK – so that the characteristic Asp633/Arg528 hydrogen bond shown in Figure 
2.4 (between activation loop and αC helix) cannot form.   
Of the two TrkA TKD structures in the PDB, one (entry 4AOJ) has an inhibitor bound 
(AZ-23), which forces the Asp-Phe-Gly motif into an “in” (rather than “out”) conformation, 
and much of the activation loop is missing.  Otherwise, this structure closely resembles 
the TrkA structure described here.  There are three molecules in the 4AOJ asymmetric 
unit, but no crystallographic or non-crystallographic packing mode is shared with our 
TrkA structure.  Recently published inhibitor-bound TrkB (Bertrand et al., 2012) and TrkC 
(Albaugh et al., 2012) structures also closely resemble our TrkA structure, although all 
but one (PDB code 4ASZ (Bertrand et al., 2012)) has an inhibitor bound, either 
displacing the DFG motif or flipping it into an “in” configuration.  A TrkA structure with no 
inhibitor bound (Bertrand et al., 2012) was subsequently released (PDB entry 4F01).  
This closely resembles our structure and, interestingly, does appear to share one 
crystallographic dimer interface as described below. 
We used the PISA (Protein Interfaces, Surfaces and Assemblies) server (Krissinel and 
Henrick, 2007) to search the PDB for crystal packing modes between TKDs similar to 
those seen for our Ror2 and TrkA structures.  No examples were seen of TKDs that 
pack like Ror2, but close relatives of one of the TrkA crystallographic dimers were seen 
both in inhibitor-bound TrkC (PDB entry 3V5Q (Albaugh et al., 2012)) and eight PDB 
entries describing structures of the inactive TKD from fibroblast growth factor receptor-1 
(FGFR1).  This crystallographic TrkA dimer is shown in Figure 2.5A.  A total surface 
area of 1,314 Å2 is buried in the interface of this dimer, in which the two copies of the αC 
helix are parallel and directly contact one another.  Further contacts are made between 
the C-terminus of the αC helix in one molecule and the C-terminus of the αE helix in its 
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neighbor.  In addition, the N-terminus of each molecule projects towards the active site 
of its neighbor, terminating with uninterpretable electron density within the active site – 
possibly reflecting a mode of intermolecular autoinhibition in an inactive dimer.  The N-
terminus shows similar behavior in the crystallographic TrkC dimer seen in PDB entry 
3V5Q, which buries a surface area of 1,136Å2.  Moreover, Mohammadi et al. 
(Mohammadi et al., 1996) highlighted a remarkably similar dimer when they first reported 
the structure of the inactive FGFR1 TKD (PDB entry 1FGK) – burying a surface area of 
1,657Å2.  The fact that this dimer is seen for three different inactive TKDs, including one 
(FGFR1) that is only distantly related, suggests that it may be functionally relevant for 
inactive RTK TKDs.  A second non-crystallographic TrkA TKD dimer, shown in Figure 
5B, is shared by our TrkA structure and that of Bertrand et al. (Bertrand et al., 2012) 
(PDB entry 4F01) – although was not seen for other TKDs in the PDB.  This dimer buries 
~1,500 Å2, primarily contributed by side-chains from the ‘hinge’ region that links β5 in the 
N-lobe and αD in the C-lobe, the kinase insert domain (between helices αD and αE), 
and strand β1 in the N-lobe.  These interactions could also contribute directly to TKD 
autoinhibition in an inactive dimer. 
As for many other RTKs, preformed inactive dimers of TrkA (Shen and Maruyama, 2011) 
and TrkB (Shen and Maruyama, 2012) have been reported based on crosslinking and 
complementation experiments, formation of which appears to require the intracellular 
domain.  It is possible that one or both of the symmetric dimers of TrkA TKDs shown in 
Figure 5 plays a role in stabilizing such dimers, along similar lines to a proposed 
symmetric inactive dimer of EGFR that was observed crystallographically (Jura et al., 
2009).  Since the tyrosines of the activation loop YxxxYY motif are distant from the dimer 
interface in both dimers shown in Figure 2.5, their trans-autophosphorylation following 
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extracellular nerve growth factor binding would require a substantial rearrangement of 
such an inactive dimer if it exists in cells. 
 
Figure 2.5.  Inactive TrkA TKD dimers 
Two orthogonal views of crystallographic dimers of TrkA TKDs.  One TrkA TKD is 
colored cyan, and the other grey.  (A) A dimer that is also found in an inhibitor-bound 
TrkC TKD crystal structure (PDB entry 3V5Q (Albaugh et al., 2012)) and in inactive 
FGFR1 TKD structures.  The αC helix, which is responsible for the majority of the 
interactions is labeled, as is αE, the C-terminus of which also makes contributions to the 
dimer interface.  The N- and C-termini of the TKD are marked.  Note the projection of the 
N-terminus towards the TKD active site – a feature that is also seen in the TrkC 
crystallographic dimer from 3V5Q.  (B) A dimer that is also found in another TrkA TKD 
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structure (PDB entry 4F0I (Bertrand et al., 2012)), which involves the ‘hinge’ region, 
kinase insert domain and strand β1.  This dimer could help maintain the inactive 
configuration through restraints on the hinge region, for example.  No evidence for TrkA 
TKD dimerization in solution was obtained in analytical ultracentrifugation studies (not 
shown).  Tyrosines in the YxxxYY motif within the activation loop are colored black, to 
highlight the fact that they are quite distant in this dimer from the active site of the 
neighboring TKD that may trans-phosphorylate them.  The tyrosine trans-
autophosphorylation events that lead to TrkA activation could not occur in the context of 
this inactive dimer, but would require its reorganization upon extracellular ligand binding 
– or association with additional receptor molecules. 
 
	  
2.6.  Activating mutations in IRK family TKDs 
	  
Figure 2.6 summarizes mutations found in the TKDs of IRK family receptor tyrosine 
kinases in cancer patients, from the COSMIC (Catalog Of Somatic Mutations In Cancer) 
database (Forbes et al., 2010) and a survey of the literature.  Patient mutations are 
found in all of the TKDs discussed here, except for Ron (not pictured in Figure 2.6).  
Two main points emerge from this inspection.  First, ALK and Met – IRK family TKDs 
with autoinhibitory interactions that do not involve direct occlusion of substrate- or ATP-
binding sites – have been found mutated most frequently in cancer patients.  With the 
caveat that this is a limited dataset, this observation may suggest that these TKDs are 
the most ‘vulnerable’ to mutational activation in cancer.  Second, many of the cancer-
associated mutations in ALK and Met are found in the activation loop and αC helix (red 
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in Figure 2.6), presumably reflecting an activating disruption of activation loop/αC helix 
interactions.  Only two such mutations have been reported in these regions of Ror2, 
whereas only a single example is seen in TrkA and IGF1R and no examples have been 
reported in MuSK.  Since stabilization of the autoinhibitory activation loop/αC 
interactions seen in ALK and Met (and in EGFR) is distributed over a large number of 
residues, we suggest that there are many positions at which activating oncogenic driver 
mutations can occur – which may increase their frequency.  By contrast, where 
autoinhibitory interactions involve projection of an activation loop tyrosine into the 
substrate binding site, they are more ‘focused’ on that particular tyrosine – which will 
reduce the probability of oncogenic mutation.  Accordingly, just as activating mutations in 
the TKD itself are rare in IGFR1R and MuSK, we expect them also to be quite infrequent 
in TrkA and Ror2 (and close relatives) based on the structures presented here. 
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Figure 2.6.  Somatic mutations in IRK family kinases in cancer 
IRK family TKDs in their inactive conformation (PDB IDs listed in Figure 2) are shown in 
the same orientation as Figure 1, with the activation loop colored cyan.  Sites at which 
mutations have been reported in cancer patients – in the literature or Catalog Of Somatic 
Mutations In Cancer (COSMIC: http://www.sanger.ac.uk/genetics/CGP/cosmic/) 
database (Forbes et al., 2010) – are represented as spheres, colored red if the 
mutations lie in the activation loop or αC helix.  Note that the region of contact between 
the activation loop and αC helix is the site of many mutations in Met and ALK.  TKDs 
without this autoinhibitory feature have fewer mutations to date, and fewer in the 
activation loop or αC.  These analyses identify a vulnerability in ALK and Met for 
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oncogenic mutations as described in the text.  Ron is not included because no mutations 
in this TKD have yet been described.  IRK is included for comparison. 
 
 
2.7.  Conclusions 
	  
In conclusion, we describe crystal structures of the TrkA and Ror2 TKDs in their inactive 
states.  The structures reveal that TrkA closely resembles IRK in its mode of 
autoinhibition (and presumably activation), relying only on occlusion of the substrate- 
and ATP-binding sites by the activation loop.  On the other hand, Ror2 autoinhibition 
combines several elements; its activation loop occludes the substrate- and ATP-binding 
sites as seen in IRK, but with additional unique contributions from a tyrosine side-chain 
close to the gatekeeper residue.  Moreover, interactions between the activation loop and 
αC contribute to Ror2 autoinhibition, suggesting that additional sites of vulnerability for 
activating mutations in Ror2 may exist that are not present in IRK, IGF1R and TrkA.  We 
also describe a model for an inactive TrkA TKD dimer that closely resembles inactive 
dimers seen for the TKDs of TrkC and FGFR1. 
Accession codes.  Coordinates and structure factors of the TrkA and Ror2 TKDs have 
been deposited with PDB under the accession codes 4GT5 (TrkA) and 4GT4 (Ror2). 
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Chapter 3:  
Origin of signaling differences between TrkA and TrkB 
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3.1.   Introduction 
	  
Receptor tyrosine kinases (RTKs) play a central role in the fate of the cell by transmitting 
extracellular signals across the cellular membrane to initiate signaling cascades that 
dictate various cellular behaviors in response to ligand binding to a specific RTK. Ligand 
binding to the extracellular domain of RTKs promotes oligomerization, in turn activating 
trans-autophosphorylation of the intracellular tyrosine kinase domains (TKD). 
Autophosphorylation of the TKD activates the kinase further and also produces docking 
sites for downstream signaling molecules. Engagement of these signaling pathways 
leads to various cellular outcome such as proliferation, differentiation, or apoptosis 
(Lemmon and Schlessinger, 2010).  As with many kinases, aberrant activity of TKDs 
either by mutation or altered expression can causes disease.  Hence, kinase activity is 
exquisitely controlled by various factors including autoregulatory mechanisms and 
substrate specificity (Lemmon and Schlessinger, 2010; Ubersax and Ferrell, 2007). 
TrkA and TrkB are members of the tropomyosin-related kinase (Trk) neurotrophin family 
of RTKs and are the receptors for nerve growth factor (NGF) and brain-derived growth 
factor (BDNF), respectively. Even though TrkA and TrkB appear to engage similar 
signaling networks when activated by their respective ligands, several studies have 
shown that activation of TrkA and TrkB in the same cell type can produce quite different 
cellular outcomes or responses. One important clinical example is seen in 
neuroblastoma, where TrkA expression (and activation) promotes cell differentiation and 
a favorable prognosis, whereas TrkB expression and activation causes cell proliferation 
and a grave prognosis for neuroblastoma patients (Borrello et al., 1993; Kogner et al., 
1993; Matsumoto et al., 1995; Nakagawara et al., 1994a; 1993; 1994b; Suzuki et al., 
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1993). How can two homologous RTKs, both thought to engage similar downstream 
signaling pathways, produces opposite cellular responses?  
Classical studies in rat pheochromocytoma (PC12) cells investigating RTK signaling 
involved in differentiation and proliferation upon activation of endogenous TrkA and 
EGFR (or IRK), respectively, showed that TrkA activation results in a sustained 
phospho-Erk response whereas activation of EGFR results in a transient phospho-Erk 
response (Marshall, 1995; Murphy and Blenis, 2006). The duration of Erk activation has 
been shown to correlate directly with differentiation (sustained) or proliferation (transient) 
by phosphorylation-dependent regulation of immediate early gene product stability 
(Murphy et al., 2004). Other studies have demonstrated that feedback loops are involved 
in creating a sustained signal (positive feedback) versus a transient signal (negative 
feedback) (Murphy and Blenis, 2006). Yet, a question still remains as how the input of 
the signaling cascade affects the dynamics of the network. Overexpression of EGFR (or 
IRK) results in a sustained phospho-Erk signal and cellular differentiation indicating that 
the strength of signal from an RTK is an essential determinant of the cellular response 
(Dikic et al., 1994; Traverse et al., 1994). 
Differences in receptor signal strength can be influenced by receptor intrinsic kinase 
activity, receptor density, receptor endocytosis and trafficking (Murphy and Blenis, 
2006). The intrinsic kinase activity of RTKs is central to the function of RTKs and could 
affect other processes such as receptor trafficking. Thus, examination of the intrinsic 
kinase activities of the RTK TKDs is a first step for assessing the origin of any signaling 
differences. 
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Our hypothesis is that intrinsic properties of the TKDs of the relevant RTKs might define 
the differences in dynamics and nature of the responses to the individual receptors.  For 
example, differences in the properties of the closely related TrkA and TrkB kinases may 
play a role in the disparate cellular response upon TrkA and TrkB activation in certain 
cell types.  Varying levels of catalytic activity and autophosphorylation between highly 
homologous kinases often involved in distinct cellular phenotypes has been reported for 
the Tec family, Src family, and FGFR family of kinases (Iseki et al., 1999; Joseph et al., 
2013; Latour et al., 1996; Lew et al., 2007).  In the case of the Tec family, a recent report 
showed that a difference of six amino acids in the activation loop of Itk and Btk was the 
source of Btk’s increased kinase activity. An Itk kinase harboring Btk’s activation loop 
was more active and produced an elevated and sustained phospho-Erk signal in T cells 
(Joseph et al., 2013). 
In this study, we investigated whether there are differences in kinase activity between 
TrkA and TrkB TKDs. We show that TrkA autophosphorylates itself faster than does 
TrkB. However, this difference of autophosphorylation is not due to a difference in kinase 
activity per se, since the kinetic parameters of TrkA and TrkB TKDs were all very similar 
when phosphorylation of peptide substrates was assessed. We also report data 
suggesting that the difference in autophosphorylation may be due to self-association of 
the TrkA TKD that does not occur with its TrkB counterpart. This study sheds light on 
potential differences between TrkA and TrkB signaling as well as providing a deeper 
quantitative understanding of Trk TKD activation, which is potentially useful for effective 
and selective inhibitor design. 
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3.2.  Generation and characterization of TrkA and TrkB kinase domain 
constructs. 
	  
A sequence and structure alignment (Figure 3.1) was performed to facilitate the design 
of analogous TrkA (residues 498-796) and TrkB (residues 542-838) TKD constructs used 
for protein expression. The TKD constructs used in this study also contain the C-terminal 
tail (C-tail) since the C-tail in the Trk receptors is only 15 amino acids long. Notice that 
the TKDs are very similar except for the kinase insert domain (KID). The TrkA and TrkB 
kinase domain proteins were expressed in baculovirus-infected Sf9 cells and purified as 
described in Materials and Methods (Chapter 5). Circular dichroism (CD) spectroscopy 
was first used to assess general secondary structure features of TrkA and TrkB. As seen 
in Figure 3.2A, the general profiles of TrkA and TrkB are very similar and indicative of 
both proteins being similarly folded and over 65% α-helix (as expected). To assess the 
thermal stability of these proteins, I also performed temperature melts monitored by CD 
spectroscopy.  TrkA and TrkB TKD proteins were diluted into a compatible buffer for CD 
analysis (25mM NaH2PO4 K2HPO4 pH7.4, 150mM NaCl) at a concentration of 2 µM, 
and were subjected to increasing temperatures from 1 to 97°C (See Chapter 5, Materials 
and Methods), and CD was monitored at 222 nm (the α-helix signature minimum). The 
apparent Tm values for both the TrkA and TrkB TKDs were above 37°C (Figure 3.2B), 
indicating that these proteins are stable during the experimental conditions I used to 
study these proteins.  Specifically, Tm values were 39.5˚C and 47.9˚C for TrkA and TrkB 
TKDs respectively. Sedimentation equilibrium analytical ultracentrifugation experiments 
were also performed to ensure that the TrkA and TrkB TKD proteins do not aggregate in 
solution. As shown in Figure 3.3, both TrkA and TrkB TKDs are primarily monomeric in 
solution at concentrations of 16.7 µM and 17.6 µM, respectively, with apparent molecular 
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weights of 35 kDa for TrkA-TKD and 31 kDa for TrkB-TKD. The residuals for a fit of the 
data to a single monomeric species were small and randomly distributed, indicating no 
systematic deviation (and therefore a reasonable fit). 
 
 
Figure 3.1. Alignment of TrkA and TrkB intracellular domains.  
A sequence alignment of human TrkA (P04629-1) and TrkB (Q16620-4) intracellular 
domains showing the secondary structure for the TrkA TKD used to design constructs. 
Indicated on the alignment are the boundaries of the TrkA and TrkB constructs. The N-
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terminal boundary immediately precedes the kinase domain, whereas the C-terminal 
boundary of the construct coincides with the C-terminus of the full-length protein. Also 
shown below the sequences are key motifs of each kinase domain including the hinge 
region (blue box), kinase insert domain (KID, magenta box) and the activation loop (grey 
box). Clustal Omega was used to generate the alignment and ESPript 
(http://espript.ibcp.fr) was used to generate the figure (Gouet, 2003; Sievers et al., 
2011). 
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Figure 3.2. TrkA and TrkB TKDs have similar secondary structure composition 
and are stable at 37°C.  
(A) The CD spectra of TrkA and TrkB TKDs show similar features indicating that neither 
of these constructs are grossly misfolded. The predicted helix and sheet composition 
determined by the K2D3 server (Louis-Jeune et al., 2011) is 69.7% helix and 1.5% sheet 
for TrkA-TKD and 66.2% helix and 2.9% sheet for TrkB-TKD. CD measurements in the 
far UV spectral region (195-260 nm) were performed on an Aviv 62A DS 
spectropolarimeter.  (B) Plotting the CD thermal melts of TrkA and TrkB TKDs 
demonstrate that both proteins are stable at 37°C.  Samples were heated from 1°C to 
97°C in 1°C increments with the circular dichroism at 222 nm being measured at each 
step. 
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Figure 3.3. TrkA and TrkB TKDs are largely monomeric in solution.  
Sedimentation equilibrium (SE) analytical ultracentrifugation (AUC) experiments were 
performed with 16.7 µM of TrkA-TKD and 17.6 µM of TrkB-TKD to assess protein self-
association. To analyze the data, the natural logarithm (ln) of absorbance at 280 nm was 
plotted against a function of the radius squared (r
2
-ro
2
)/2, where r is the radial position in 
the sample and ro is the radial position of the meniscus. This analysis provides a straight 
line (for a single species) with slope proportional to the molecular mass of the species. 
Data collected at 10,000 rpm with best-fit lines are shown for TrkA-TKD (A) and for TrkB-
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TKD (B).  The apparent molecular weights calculated for the TrkA and TrkB TKDs are 35 
kDa and 31 kDa, respectively. The predicted molecular weights based on sequence for 
TrkA and TrkB TKDs are 34.8 kDa and 35.1 kDa, respectively.  It is important to note 
that the TrkA-TKD sample for AUC was not treated with phosphatases during purification 
whereas the TrkB sample was treated with phosphatases during purification. 
Regardless, the apparent molecular weights suggest that these proteins are mostly 
monomeric in solution and there are no signs of significant aggregation.  
 
	  
3.3.  An autophosphorylation assay reveals differences between TrkA and 
TrkB TKDs. 
	  
Autophosphorylation of the Trk receptors following their activation is well established 
(Kaplan et al., 1991a; 1991b; Klein et al., 1991a; 1991b; Soppet et al., 1991; Squinto et 
al., 1991). The full-length Trk receptors contain five known sites of autophosphorylation. 
Three sites reside in the activation loop as part of the YxxxYY motif, one site lies in the 
juxtamembrane (JM) region, and another lies in the C-terminal tail (CT) (Guiton et al., 
1994; Loeb et al., 1994; Middlemas et al., 1994; Stephens et al., 1994). The TrkA and 
TrkB TKDs used for this study do not contain the JM region – since its removal was 
necessary for the production of high levels of homogenous protein – so I only monitored 
phosphorylation at four tyrosines in my in vitro studies. 
For an initial qualitative approach to visualizing the progression of TrkA and TrkB TKD 
autophosphorylation, I used native PAGE. However, the native gels were difficult to 
interpret due to more than expected species identified on the gels (Figure 3.4). We 
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speculate that these species may arise from heterogeneity of the starting material arising 
from various types of post translational modification (see below results from mass 
spectrometry of the starting material), or different combinations of 
autophosphosphorylation site usage. 
For a better, more quantitative, approach to monitoring progression of 
autophosphorylation, I added trace amounts of γ-32P ATP to the autophosphorylation 
reaction and visualized its incorporation into the TKD by SDS PAGE-based 
autoradiography. The image captured by a Phoshorimager was then analyzed using 
ImageStudio software, and normalized using the near infrared fluorescence signal from 
protein-bound Coomassie blue stain from the same gel. As shown in Figure 3.5, TrkA 
TKD autophosphorylation occurred faster than TrkB TKD autophosphorylation at both 
37° and RT. Interestingly, once both TrkA-TKD and TrkB-TKD autophosphorylation 
peaked, there was an apparent loss of signal over time. This presumably represents 
dephosphorylation of the TrkA and TrkB TKD proteins. 
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Figure 3.4. Initial native PAGE analysis of TKD autophosphorylation.  
Native gels of samples from autophosphorylation reactions with (A) TrkA TKD and (B) 
TrkB TKD at 10 µM, incubated at 37°C for the indicated times. Both of these constructs 
have four tyrosines that are known to be autophosphorylated, yet at times there are 5-6 
bands on the native gel, presumably reflecting different combinations of 
autophosphorylation site usage or due to heterogeneous starting material. 
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Figure 3.5. TrkA-TKD autophosphorylates faster than TrkB-TKD.  
(A) Autoradiographs and Coomassie gel of a time course of TrkA and TrkB TKD 
autophosphorylation, using 10 µM protein at 37°C. (B) Quantitation of the 
autoradiography signal normalized by the amount of protein in each lane detected by 
Coomassie stain for the autophosphorylation reactions at 37°C. (C) Autoradiographs and 
Coomassie gel of autophosphorylation reactions performed at RT. (D) Quantitation of 
the RT autophosphorylation experiment as described above. 
  
63	  
	  
3.4.  TrkA and TrkB TKDs autodephosphorylate in a similar manner 
	  
As mentioned above, the initial autophosphorylation reactions demonstrated a loss of 
32P signal over time.  It was important first to determine whether this reflected a 
contaminating phosphatase, since phosphatase contamination would impact the 
interpretation of the autophosphorylation assays. Mass spectrometry analysis of the 
purified product did show trace amounts of the baculovirus phosphatase (BVP). BVP 
was initially classified as a protein phosphatase, but subsequent reports have suggested 
that BVP is only a modest protein phosphatase and is a much more potent RNA 5’-
triphosphatase (Takagi et al., 1998).  Furthermore, the activity of BVP is greatly reduced 
by 1 mM MgCl2 or 200 µM sodium vanadate (Gross and Shuman, 1998; Kim and 
Weaver, 1993; Sheng and Charbonneau, 1993). The TrkA and TrkB 
autophosphorylation reactions contain 10 mM MgCl2, arguing that BVP should be 
inhibited under these reaction conditions.  
That the observed dephosphorylation was not simply due to a contaminating 
phosphatase was demonstrated by experiments using several different phosphatase 
inhibitors including sodium vanadate and the ‘Halt’ phosphatase inhibitor cocktail. None 
of these treatments significantly altered the dephosphorylation profile as compared with 
the control experiment lacking phosphatase inhibitors (Figure 3.6). Moreover, 
preparations generated using a new purification scheme were more homogeneous (see 
Chapter 3.5) and showed no signs of phosphatase contamination by mass 
spectrometric analysis.   
There are numerous scattered reports in the literature demonstrating ‘futile’ ATPase 
activity of kinases, reversal of the kinase reaction, or substrate dephosphorylation by 
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kinases (Al-Hasani et al., 1994; Argetsinger and Shafer, 1992; Bae et al., 2010; Chen et 
al., 2000; Favelyukis et al., 2001; Fukami and Lipmann, 1983; Gruppuso et al., 1992; 
Kim et al., 2001; Mendelow et al., 1993; O'Brian and Ward, 1991; Parast et al., 1998; 
Paudel and Carlson, 1991; Pike et al., 1986; Ward and O'Brian, 1992; Yang et al., 2004).  
PKA, PKC, phosphorylase kinase, and p38 MAP kinase have all been shown to have 
intrinsic ATPase activity.  For PKA and PKC, at least, this ATPase activity is dependent 
on solvent accessibility of the substrate binding pocket (Chen et al., 2000; Mendelow et 
al., 1993; O'Brian and Ward, 1991; Paudel and Carlson, 1991; Ward and O'Brian, 1992; 
Yang et al., 2004). There are reports that Src, CaM-kinase II, VEGFR2 TKD, and IRK 
can reverse the kinase reaction with generation of ATP – in an ADP-dependent manner 
(Argetsinger and Shafer, 1992; Fukami and Lipmann, 1983; Kim et al., 2001; Parast et 
al., 1998; Pike et al., 1986). On the other hand, there are clear reports of IRK 
autodephosphorylation generating free inorganic phosphate – which is inconsistent with 
reversal of the kinase reaction. These IRK studies showed that autodephosphorylation is 
dependent on the kinase active site, since staurosporine (a promiscuous ATP 
competitive kinase inhibitor) and EDTA both abolish dephosphorylation (Al-Hasani et al., 
1994; Gruppuso et al., 1992). There is additional evidence in the literature of 
autodephosphorylation of IGF1R and FGFR1 (Bae et al., 2010; Favelyukis et al., 2001).  
Thus, there is clear precedent for the observation that RTKs autodephosphorylate. It is 
important to note that many of the above mentioned kinases utilize some variation of 
pseudosubstrate autoinhibition as a mechanism of autoregulation. 
Autodephosphorylation of the TrkA and TrkB TKDs occurred to varying degrees 
depending on the reaction conditions. One of the factors that seemed to play a role in 
dephosphorylation was the concentration of Trk TKD protein, as shown for TrkA in 
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Figure 3.7. Higher concentrations (10 µM TrkA) clearly accelerate autophosphorylation 
as well as autodephosphorylation compared to reactions with 1 µM TrkA, suggesting that 
both may be intermolecular reactions. 
Taken together, the dephosphorylation of TrkA and TrkB TKDs appears unlikely to be 
caused by phosphatase contamination. I decided not to pursue the 
autodephosphorylation of TrkA and TrkB TKDs any further, since this is a phenomenon 
reported in the literature for other kinases, and appears to be substantially slower than 
basal RTK dephosphorylation by protein tyrosine phosphatases that is seen in a cellular 
context (Kleiman et al., 2011).  Moreover, autodephosphorylation occurs in a similar 
manner for both TrkA and TrkB TKDs (Figure 3.5), so is unlikely to be an important 
factor that underlies their signaling differences. These data do argue that the difference 
in rates of autophosphorylation between TrkA and TrkB TKDs is intrinsic to their TKDs, 
however, and is not simply due to contaminating phosphatases. 
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Figure 3.6. Phosphatase inhibitors do not affect dephosphorylation of TrkA-TKD. 
 Autophosphorylation reactions of TrkA-TKD at 10 µM were performed in the absence of 
phosphatase inhibitor as in Figure 3.4, but also in the presence of sodium vanadate, 
‘Halt’ cocktail phosphatase inhibitor (including sodium fluoride, sodium orthovanadate, 
sodium pyrophosphate, and β-glycerophosphate), or ‘PhosStop’ cocktail phosphatase 
inhibitor (a proprietary blend of phosphatase inhibitors). (A) Autoradiographs and 
Coomassie gel of a time course of TrkA-TKD autophosphorylation at 37°C without or 
with phosphatase inhibitors. (B) Quantitation of the autoradiography signal normalized 
by the amount of loaded protein detected by Coomassie stain. 
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Figure 3.7. Concentration dependence of autodephosphorylation of TrkA-TKD. 
Autophosphorylation reactions were performed either with 1µM or 10 µM TrkA-TKD.  
(A) Autoradiographs and Coomassie gel of TrkA-TKD autophosphorylation at 37°C. 
(B) Quantitation of the autoradiography signal normalized by the amount of protein 
loaded detected by Coomassie stain. 
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3.5.  Optimizing purification scheme to ensure homogenous TKDs as 
starting material 
	  
Initial attempts to analyze the autophosphorylation of TrkA and TrkB TKDs suggested 
that the proteins from Sf9 cells are modified. SDS PAGE Western blotting with a general 
phosphotyrosine antibody (pY20) of TrkA and TrkB TKD autophosphorylation reactions 
did not yield detectable signal at the zero minute time point. However, there was a weak 
signal from one of the phosphospecific antibodies (pY676) for both TKDs, demonstrating 
that the starting material is phosphorylated (shown clearly in Figure 3.10).  Figure 3.8 
shows that TrkA TKD autophosphorylates faster than TrkB-TKD, but we were concerned 
about interpreting these results if the two proteins are differently modified during 
overexpression in Sf9 cells. I therefore used the PhosTag gel approach to further 
monitor phosphorylation of the starting material and the autophosphorylation reactions. 
PhosTag gels are polyacrylamide gels with the PhosTag acrylamide reagent coordinated 
with Zn2+ in the resolving gel. Phosphorylated species bind to the acrylamide-associated 
metal and hence migrate more slowly during gel electrophoresis (Kinoshita and 
Kinoshita-Kikuta, 2011). It is evident by Coomassie stain and Western blotting of 
autophosphorylation reactions analyzed on PhosTag gels that the starting material 
(0 minute time point) is already modified to some degree, particularly for the TrkB TKD 
(Figure 3.8C,D) 
We performed LC MS/MS mass spectrometry to investigate post translational 
modification of the TrkA and TrkB TKD starting material.  Figure 3.9 shows the peptides 
identified and post translational modification of the TrkA-TKD and TrkB-TKD starting 
material. These mass spectrometry data confirmed the Western blotting data that both 
TrkA and TrkB TKDs were tyrosine phosphorylated to some degree. To address 
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heterogeneity concerns of the starting material, I therefore developed a purification 
scheme including phosphatase treatments and additional steps of purification (see 
Chapter 5, Material and Methods). As shown in Figure 3.9 and Figure 3.10, this new 
purification scheme was successful in producing a more homogenous sample as well as 
ensuring no phosphatase contamination.  Figure 3.9C,D shows there is much less post 
translational modification of the TrkA and TrkB TKD samples following the optimized 
purification scheme. There are still trace amounts of phosphorylation of TrkA and TrkB 
TKDs, but not in the regions of the TKD that we are most concerned with, namely the 
activation loop and the C-terminal tail.  Phosphospecific Western blotting was also used 
to examine sample quality of the TrkA-TKD and TrkB-TKD starting materials during all 
subsequent optimized purifications (Figure 3.10). 
 
70	  
	  
 
Figure 3.8. Initial assessment of TKD autophosphorylation by phosphospecific 
antibodies and PhosTag gels.  
TrkA-TKD and TrkB-TKD autophosphorylation assays were analyzed using SDS PAGE 
Western blotting probed with Trk antibodies (red) and phosphospecific antibodies 
(pY676, pYY680/681, pY791; human TrkA isoform II numbering) (green). (A) SDS PAGE 
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Western blots of TrkA and TrkB TKD autophosphorylation reactions and (B) quantitation 
of the normalized signals from these plots. (C) PhosTag SDS PAGE Western blots and 
(D) Coomassie stained PhosTag gel of TrkA and TrkB TKD autophosphorylation 
reactions. 
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Figure 3.9. Mass Spectrometry analysis of TrkA-TKD and TrkB-TKD plus or minus 
phosphatase treatment. TrkA-TKD (A) and TrkB-TKD (B) samples not treated with 
phosphatases. TrkA-TKD (C) and TrkB-TKD (D) samples treated with phosphatase and 
subject to more purification steps. Samples were submitted to the Wistar Institute 
proteomic facility for in-solution digestion and LC-MS/MS analysis. The amino acid 
peptide coverage of the mass spectrometry analysis is showed by grey lines below the 
Trk sequences. Modified residues are highlighted in green (oxidation), purple 
(acetylation), and brown (phosphorylation). The activation loop (boxed region in the 
peptide coverage map) tyrosines are no longer phosphorylated after phosphatase 
treatment.   
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Figure 3.10. Monitoring protein phosphorylation during purification. 
 (A) Phosphospecific Western blotting of purified protein stock that was also used for the 
LC-MS/MS mass spectrometry analysis. (B) PhosTag SDS PAGE phosphospecific 
Western blotting of TrkA and TrkB TKD samples taking during the phosphatase 
treatment phase of the optimized purification scheme. (C) Another example of PhosTag 
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SDS PAGE phosphospecific Western blotting of TrkA-TKD during protein purification to 
ensure the starting material is mostly dephosphorylated. 
 
 
3.6.  TrkA-TKD autophosphorylates faster than TrkB-TKD, and the order of 
phosphorylation site usage is the same for both TrkA and TrkB TKDs. 
	  
The sequential order of phosphorylation has been shown to be vital for stepwise 
increments of kinase activity for kinases that are dependent on phosphorylation of 
activation loop residues for full activity (Favelyukis et al., 2001; Furdui et al., 2006). 
Thus, differences in order can impact both the autophosphorylation profile and ultimate 
kinase activity. Studies with FGFR, EGFR and Ret RTKs have shown that pathogenic 
mutations can disturb the autophosphorylation order of the WT receptor, illustrating 
further that differences in order of autophosphorylation can impact cellular phenotype in 
important ways (Kim et al., 2012; Lew et al., 2009; Plaza-Menacho et al., 2014). 
The autophosphorylation sites of TrkA and TrkB have been identified previously, and 
autophosphorylation occurs at analogous sites in TrkA and TrkB (Guiton et al., 1994; 
Loeb et al., 1994; Middlemas et al., 1994; Stephens et al., 1994).  The order of 
phosphorylation of these sites has not been directly studied for either TrkA or TrkB.  
Comparison of the published order of autophosphorylation for other members of the IRK 
TKD family (Table 3.1) reveals a diversity that does not necessarily correlate with the 
class of activation loop conformation discussed in Chapter 2. IRK autophosphorylation 
proceeds in the same order as seen for IGF1R, but autophosphorylation of the MuSK, 
Met and Alk kinases are all distinct. The Met and Alk activation loop conformations (in 
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their inactive structures) are distinct from other IRK TKD family members (Figure 2.2), 
so it is not surprising that these kinases employ different orders of autophosphorylation 
from that seen with IRK and IGF1R. However, the MuSK TKD activation loop 
superimposes very well with IRK, IGF1R and TrkA in crystal structures (Figure 2.2), so it 
seems surprising that MuSK employs a different order of autophosphorylation site usage 
than IRK and IGF1R. This observation also opens up the question as to what is the site 
usage order in the Trk TKDs. 
Table 3.1. Previously reported autophosphorylation orders for the IRK TKD family. 
RTK 1st Site 2nd Site 3rd Site Sequence References 
IRK YxxxpYY pYxxxpYY pYxxxpYpY Y1162, 
Y1158, 
Y1163 
(Wei et al., 1995) 
IGF1R YxxxpYY pYxxxpYY pYxxxpYpY Y1135, 
Y1131, 
Y1136 
(Favelyukis et al., 2001) 
MuSk YxxxpYY & 
JM-pY 
pYxxxpYpY - Y754/Y552, 
Y750/Y755 
(Till et al., 2002) 
Met YxxxYpY YxxxpYpY  Y1235, 
Y1234 
(Chiara, 2003) 
Alk pYxxxYY - - Y1278 (Donella-Deana et al., 
2005) 
 
 
I used Western blotting with phosphospecific antibodies to visualize the order of 
autophosphorylation for the TrkA and TrkB TKDs. The concentrations of Trk TKD used 
for the autophosphorylation experiments were between 1 µM and 10 µM which is 
consistent with the estimated concentration of RTKs on the cell surface (Lemmon et al., 
1997). The antibodies used recognize phosphorylation at either the first tyrosine of the 
pYxxxYY motif (anti pY676; TrkA numbers are listed), the second and third tyrosines of 
the YxxxpYpY motif (anti pYY680/681) or the C-terminal tail tyrosine (anti pY791) of 
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TrkA and TrkB. The specificity of antibodies targeting Trk autophosphorylation 
(pYY680/681 and pY791) sites has been previously tested with mutagenesis and 
peptide competition assays (Choi et al., 2001; Segal et al., 1996).  
TrkA and TrkB TKD autophosphorylation assays were conducted at 15°C in order to be 
able to distinguish differences, and samples taken at the different time points were 
subjected to either SDS PAGE or PhosTag SDS PAGE for Western blotting and 
Coomassie staining. Each Western blot was probed with a phosphospecific antibody and 
a total Trk antibody. For the SDS PAGE Western blots each phosphospecific signal was 
normalized for total Trk. Normalized signal from a phosphospecific antibody was then 
expressed as a fraction of the maximum signal seen with that antibody for TrkA or TrkB 
autophosphorylation respectively. Using these data, the normalized relative signals for 
each phosphospecific antibody could be compared directly between sites and TKDs 
(Figure 3.11). Quantitation of these Western blots revealed once again that TrkA TKD 
autophosphorylation at all sites occurs more rapidly than that seen for the TrkB TKD.  
The order of autophosphorylation, however, appears to be the same for TrkA and TrkB 
TKDs in the context of the phosphospecific antibodies used here to monitor 
autophosphorylation.  PhosTag SDS PAGE was utilized to further characterize the order 
and rate of autophosphorylation of TrkA and TrkB TKDs. The PhosTag acrylamide 
reagent coordinates Zn2+, which is able to bind phosphates of any phosphorylated 
species. Binding of the phosphorylated proteins to PhosTag-Zn2+ lowers their mobility, 
resulting in band shifts related to the number of phosphates incorporated in a particular 
phosphorylated species (and thus the degree of PhosTag-Zn2+) binding. 
Phosphospecific Western blotting was used to identify the various phosphorylated 
species during a time course of autophosphorylation (Figure 3.11). Assignment of the 
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phosphorylated species is shown on the Coomassie-stained gel in Figure 3.11D. The 
data from various SDS PAGE and PhosTag SDS PAGE phosphospecific Western blots 
were compiled to determine the order of autophosphorylation for TrkA and TrkB TKDs. 
The autophosphorylation experiments were repeated under various conditions, and the 
rate of TrkA-TKD autophosphorylation was always faster than seen with TrkB-TKD.  
Furthermore, the order of autophosphorylation for TrkA and TrkB TKDs appeared to be 
similar for all the conditions we tested. For example, the conclusions made above for the 
autophosphorylation reactions at 15°C hold true for autophosphorylation reactions 
performed at 37°C and monitored by phosphospecific Western blotting as described 
above (Figure 3.12). 
Monitoring autophosphorylation by Western blotting with phosphospecific antibodies 
does have some limitations. First, there may be other sites of autophosphorylation that 
we are missing in this analysis. However, if there were additional sites of 
autophosphorylation, we would have expected the presence of additional bands or a 
different band pattern on the PhosTag gels. Another caveat to using phosphospecific 
antibodies is that resolution can be limited if there is an antibody that recognizes more 
than one site. One of the antibodies does recognize a dual phosphorylation event in the 
activation loop (YxxxpYpY), and the specificity of this antibody as been previously tested 
(Segal et al., 1996). Unfortunately, there are no reliable commercially available 
antibodies for either of the corresponding singly phosphorylated species.  Thus, the first 
autophosphorylation event of TrkA-TKD and TrkB-TKD that was detected was by the 
dual specific antibody.  There are mass spectrometry based experiments that I could 
have utilized to examine further the first autophosphorylation event. However, I decided 
not to pursue any further the order of autophosphorylation since the order of 
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autophosphorylation appeared to be similar for TrkA and TrkB TKDs and my goal was to 
investigate differences between these TKDs.   
Intriguingly, the order of autophosphorylation site usage for TrkA and TrkB TKDs 
appears to resemble that seen for Met, rather than IRK/IGFR1 (Table 3.1), with tyrosines 
680 and 681 (TrkA) being phosphorylated essentially at the same time (or in no defined 
order).  Both TrkA and TrkB TKDs gave the same results under the conditions we tested.  
The elevated rate of TrkA-TKD autophosphorylation compared to that seen for TrkB-
TKD is clear and reproducible in these experiments, and could possibly underlie some of 
the observed signaling differences. 
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Figure 3.11. Autophosphorylation is a similarly ordered process for TrkA and TrkB 
TKDs.  
Autophosphorylation assays performed at 15°C with 5 µM TrkA and TrkB TKDs in the 
presence of 1 mM ATP and 10 mM MgCl2 in a buffer containing 100 mM HEPES pH 7.4, 
150 mM NaCl, 2 mM DTT and ‘Halt’ phosphatase cocktail inhibitor. Samples were taken 
at the indicated times and analyzed by SDS PAGE and PhosTag SDS PAGE Western 
blotting and Coomassie stain. (A) SDS PAGE Western blotting with phosphospecific 
antibodies specified to the left of the images. (B) The normalized relative signals from 
the Western blots were determined first by normalizing each phosphospecific signal with 
the total Trk signal. Each normalized signal was then divided and by the maximum signal 
per phosphospecific antibody per reaction. The resulting plot of normalized relative 
signal of each phosphospecific antibody clearly shows that TrkB-TKD 
autophosphorylation is slower than TrkA-TKD autophosphorylation. This analysis also 
reveals that the order of autophosphorylation appears to be similar for the TrkA and TrkB 
TKDs. (C) PhosTag SDS PAGE Western blotting with phosphospecific antibodies. (D) 
Coomassie stained PhosTag gel of autophosphorylation reaction with bands labeled 
according to phosphospecific Western blotting experiments. 
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Figure 3.12. Autophosphorylation of TrkA and TrkB TKDs at 37°C. 
 Autophosphorylation assays performed at 37°C with 1 µM TrkA and TrkB TKDs in the 
presence of 1 mM ATP and 10 mM MgCl2 in a buffer containing 100 mM HEPES pH 7.4, 
150 mM NaCl, 2 mM DTT and ‘Halt’ phosphatase cocktail inhibitor. Samples were taken 
at the indicated times and analyzed monitored by SDS Western blotting with 
phosphospecific antibodies. (A) Two-color Western blots probed with the indicated 
phosphospecific antibodies (green signal) and pan Trk antibodies (red signal). (B) The 
normalized relative signals from the Western blots were determined by normalizing each 
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phosphospecific signal with the total Trk signal, and then dividing each normalized signal 
by the maximum signal per blot. The normalized relative signal is plotted for each 
antibody and shows that all the TrkA-TKD autophosphorylation events occur before the 
TrkB-TKD autophosphorylation events at this TKD concentration. 
 
 
3.7.  Kinetic parameters of TrkA and TrkB TKD peptide phosphorylation do 
not explain differences in autophosphorylation rates 
	  
The difference in autophosphorylation shown for the TrkA and TrkB TKDs could be a 
result of a difference in the intrinsic kinase activities of the two species. To test this 
hypothesis, I employed a more quantitative analysis of enzyme activity, monitoring 
kinase activity by following the incorporation of 32P from 32P-γ-ATP into a peptide 
mimicking the activation loop of either TrkA (SRDIYSTDYYRVGGRTMLPIR) or TrkB 
(SRDVYSTDYYRVGGHTMLPIR). Table 3.2 lists the kinetic parameters measured in 
these assays, and Figure 3.13 shows representative data used to obtain the kinetic 
parameters. As mentioned previously, the TrkA and TrkB TKD proteins are subjected to 
two treatments of phosphatases to ensure the proteins are fully dephosphorylated (see 
subchapter 3.5 and Chapter 5, Materials and Methods).  Experiments were 
performed both with fully dephosphorylated TKDs, in order to quantitate activity of the 
maximally autoinhibited form seen in the crystal structure described in Chapter 2, as well 
as (almost) fully phosphorylated TKDs – as a measure of maximal activity and the 
activation consequences of autophosphorylation.  To obtain phosphorylated TrkA and 
TrkB TKDs for the latter assays, autophosphorylation was allowed to proceed, and was 
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quenched at a predetermined time at which autophosphorylation was known to peak 
(prior to dephosphorylation as monitored by SDS PAGE and PhosTag SDS PAGE 
phosphospecific Western blotting). It should be noted that the phosphorylated TrkA and 
TrkB TKD preparations are heterogeneous mixes of phosphorylated species, based on 
PhosTag gels (Figure 3.14). We were unable to phosphorylate TrkA and TrkB TKDs 
completely, since allowing the autophosphorylation reaction to progress for longer also 
resulted in increased dephosphorylation – which we can only inhibit with procedures that 
will also inhibit kinase activity (see above). 
Table 3.2 shows that the inactive (unphosphorylated) TrkA and TrkB TKDs have very 
similar kinetic parameters. Upon autophosphorylation, there is a dramatic change in the 
kinetic parameters for both TrkA-TKD and TrkB-TKD.  Values for kcat increase by ~60-
100-fold, with smaller changes in Km, ATP (~10-fold reduction) and Km, peptide (~5-fold 
reduction) resulting in overall increases in catalytic efficiency in the range of 400-600 
fold.  These changes in kinetic parameters between unphosphorylated and 
phosphorylated TrkA and TrkB TKDs are in the range as those reported for other RTKs 
that rely on phosphorylation of activation loop tyrosines for full activity (Cobb et al., 1989; 
Favelyukis et al., 2001; Furdui et al., 2006; Till et al., 2002). The active TrkA and TrkB 
TKD kinetic parameters are also very similar to one another, indicating that TrkA and 
TrkB TKDs show very similar catalytic capacity when presented with a peptide substrate 
while at nanomolar concentrations. However there is a subtle difference in the catalytic 
efficiency that may contribute but not does explain the observed slower rate of TrkB-TKD 
autophosphorylation. The catalytic efficiency for ATP is ~1.8-fold decreased for TrkB-
TKD in both the inactive and active states. 
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Table 3.2 Summary of kinetic parameters of TrkA and TrkB TKDs in the inactive 
(dephosphorylated) or active (phosphorylated) states. Data are shown as mean ± 
standard deviation of at least 3 experiments. 
 kcat, ATP Km, ATP kcat/ Km, ATP kcat, peptide Km, peptide kcat/ Km, peptide 
kinase (min-1) (mM) (min-1 mM-1) (min-1) (mM) (min-1 mM-1) 
TrkA 19.7 ± 2.2 2.09 ± 0.52 9.8 ± 2.5 20.3 ± 0.6 2.18 ± 0.13 9.3 ± 0.8 
TrkB 16.6 ± 6.6 3.20 ± 1.69 5.8 ± 1.9 9.7 ± 3.2 1.17 ± 0.42 9.4 ± 5.2 
       
pTrkA 1144 ± 346 0.18 ± 0.05 6204 ± 673 1456 ± 239 0.364 ± 0.04 3991 ± 309 
pTrkB 1033 ± 421 0.29 ± 0.14 3641 ± 423 1482 ± 211 0.390 ± 0.06 3815 ± 266 
 
 
Despite this similarity in catalytic properties, it is clear that there is a reproducible 
difference in the autophosphorylation rates seen for the TrkA and TrkB TKDs. One 
important observation may provide part of the explanation for this autophosphorylation 
difference despite similar kcat and Km values in peptide phosphorylation assays. In the 
process of identifying suitable conditions for the quantitative peptide-based kinase assay 
described here, I explored many conditions. During these pilot experiments, I found that 
unphosphorylated TrkA-TKD displayed a greater dependence on concentration for 
activation than TrkB-TKD, and the effect was quite substantial. Kinase assays in which 
only TrkA or TrkB concentrations were varied are shown in Figure 3.15. Non-linear initial 
velocity plots were seen for several different TrkA TKD concentrations, evident as low as 
60 nM (Figure 3.15A), whereas initial velocities for TrkB-TKD are quite linear, even at 
386 nM protein (Figure 3.15C). The concentration dependence of TrkA-TKD activation 
is clearer in plots of initial velocity normalized for concentration.  Even higher 
concentration data overlay quite well when this is done for TrkB-TKD (Figure 3.15D), as 
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they should if there is no concentration dependence.  By contrast, none of the TrkA-TKD 
initial velocities overlay after 2 minutes (Figure 3.15B).  
It seems reasonable to propose that the concentration dependence of TrkA-TKD activity 
is related to its enhanced rate of autophosphorylation in the assays described above.  
The fact that the TrkA and TrkB TKDs appear to have similar kinase activities is striking, 
given the reproducible finding that TrkA-TKD autophosphorylation is faster than TrkB-
TKD autophosphorylation. The observations that TrkA-TKD lacks a lag phase for 
autophosphorylation and displays a strong concentration dependence of activation led 
us to explore the possibility that TrkA-TKD self-associates under the conditions of these 
experiments. 
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Figure 3.13. Representative data for obtaining enzymatic parameters for TrkA and 
TrkB TKDs.  
Michaelis-Menten plots determining Km and kcat for ATP (left) or peptide (right) 
substrates. (A) For Km, ATP  determination, dephosphorylated TrkA-TKD at 30 nM and 
dephosphorylated TrkB-TKD at 400 nM were assayed with variable ATP concentrations  
(5 mM to 0.039 mM) in the presence of fixed 2 mM peptide substrate and 10 mM MgCl2.   
(B) For Km, peptide  determination, dephosphorylated TrkA-TKD at 30 nM and 
dephosphorylated TrkB-TKD at 400 nM were assayed with variable peptide 
concentrations (4 mM to 0.031 mM), fixed 2 mM ATP and 10 mM MgCl2. (C) Km, ATP 
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determined using phosphorylated TrkA-TKD and phosphorylated TrkB-TKD, both at 8 
nM. Reaction conditions included a fixed 2 mM concentration of peptide corresponding 
to their respective activation loops, variable ATP concentrations (5 mM to 0.039 mM) 
and 10 mM MgCl2.  (D) For Km, peptide   with phosphorylated TrkA and TrkB TKDs, assays 
were performed as in (C), but peptide concentration was varied (4 mM to 0.031 mM) and 
ATP concentration fixed at 2 mM ATP. 
 
 
Figure 3.14. Generation of phospho-TKD species.  
Autophosphorylation assays were conducted to generate phosphorylated TrkA and TrkB 
TKDs for enzymatic studies. Western blotting of PhosTag gels with phosphospecific 
antibodies were used to monitor the reactions. (A) 10 µM TrkA-TKD was incubated at 
room temperature with 1 mM ATP, 10 mM MgCl2 in a buffer containing 100 mM HEPES 
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pH 7.4, 150 mM NaCl, 2 mM DTT and Halt phosphatase cocktail inhibitor. At 5 minutes, 
the reaction was quenched with EDTA to achieve a final concentration of 100mM. (B) 
7.5 µM TrkB-TKD was incubated at 30°C with 1 mM ATP, 10 mM MgCl2 in a buffer 
containing 100 mM HEPES pH 7.4, 150 mM NaCl, 2 mM DTT and Halt phosphatase 
cocktail inhibitor. At 4 minutes, the reaction was quenched with EDTA to achieve a final 
concentration of 100mM. 
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Figure 3.15. Differences in concentration dependence of activation for TrkA and 
TrkB TKDs.  
Peptide-based radioactive kinase assays with 2 mM ATP, 2 mM peptide substrate, 10 
mM MgCl2+ and various concentrations of TrkA and TrkB TKDs were used to determine 
the optimal concentration of TrkA-TKD or TrkB-TKD for further kinase assays. (A) 
Plotting the moles of phosphate incorporated versus time for each concentration of TrkA-
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TKD to determine initial rates of reactions shows curvature in most of these reaction 
profiles. (B) Normalizing initial rates for concentration of TrkA-TKD results in an obvious 
concentration dependence. (C) Initial rates for TrkB-TKD determined as above appear to 
be more linear in the higher concentrations than reactions with TrkA-TKD. (D) 
Normalized initial rates for TrkB-TKD overlay well when normalized for concentration, 
indicating that TrkB-TKD activity (unlike that of TrkA-TKD) is concentration independent. 
 
 
3.8.  TrkA-TKD crystallographic dimer not observed in TrkB-TKD crystal 
structures 
	  
In a study comparing the inactive structures of the TrkA and TrkB TKDs, Bertrand et al. 
2012 reported that the TrkA kinase insert domain (KID) interacts with the hinge region 
(loop connecting N-lobe and C-lobe), intramolecularly (Figure 3.16). Notably, Glu615 and 
Asp616 in the KID of TrkA interact with Arg593 and His594 in the hinge region, respectively, 
in the same molecule. However, none of these hinge region – KID interactions are 
observed in any of the TrkB-TKD structures now available, as a result of displacement of 
the TrkB KID by the C-terminal tail of TrkB. Hence, the authors postulated that the TrkA 
hinge region may be more rigid than the TrkB hinge region (Bertrand et al., 2012). 
Several studies have indicated that hinge region dynamics are important for catalytic 
activity of kinases such as Erk (Hoofnagle et al., 2001; 2004; Lee et al., 2005; Sours et 
al., 2014; Xiao et al., 2014). In the case of FGFR2, hinge region interactions are thought 
to serve as “brakes” that hold the kinase in an inactive conformation (Chen et al., 2007). 
In FGFR2, interactions are seen between the hinge region (β5-αD loop) and the N-lobe 
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(Chen et al., 2007). TrkA and TrkB TKDs have similar interactions between the kinase 
hinge and the N-lobe, but both have far fewer interactions than observed in FGFR2. The 
hinge region in TrkA predominantly interacts with the KID, which is part of the C-lobe 
(Bertrand et al., 2012). 
Since the TrkA TKD autophosphorylates faster than that of TrkB (and has similar activity 
in peptide phosphorylation assays), it seems highly unlikely that the intramolecular 
hinge/KID interactions seen in the TrkA-TKD structure (4F01) reduce TrkA-TKD activity.  
However, a dimer that ‘repurposes’ some of these interactions for intermolecular 
interactions, seen in a crystallographic dimer in our studies of TrkA-TKD (PDB 4GT5) 
may provide an explanation.  This dimer shares a similar interface with a crystallographic 
dimer also seen in the TrkA TKD structure reported by Bertrand et al., 2012 (PDB 4F0I) 
(Figure 2.5B) (Artim et al., 2012; Bertrand et al., 2012). The dimers observed in these 
TrkA TKD structures are slightly different, but share much of the same dimer interface 
(Figure 3.17 and Table 3.3-3.4).  The fact that TrkA-TKD activity is concentration 
dependent may suggest that it self-associates, and the interactions in this dimer may be 
important for dimerization (and possibly altered upon self-association with allosteric 
effects on kinase activity).  TrkA TKD dimerization could drive its own activation, and this 
might cause the observed difference in autophosphorylation rates between TrkA and 
TrkB. 
The two TrkA TKD crystal structures in which similar dimers were seen are from very 
similar constructs, yet the reported crystallization conditions are different. Furthermore, 
the two TrkA TKD crystal structures are described by different space groups (4GT5 
space group is H32 whereas 4F0I space group is P41212) and a different number of 
molecules are present in the asymmetric unit (4GT5 has one molecule in asymmetric 
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unit whereas 4F0I has two).  These facts suggest that the dimer may therefore have 
some relevance.  Closer inspection of this TrkA TKD dimer interface also identified 
several key residues in the kinase insert domain (KID) and hinge region of TrkA that 
form a network of interactions (Figure 3.17C). In both structures, Tyr591 and Arg593 in the 
hinge region of one monomer interact with Gly614 and Glu615, respectively in the KID of a 
symmetry mate.  Another interaction across the interface that was consistent between 
the TrkA TKD structures was the main chain carbonyl group of Leu611 in the KID of one 
monomer forming a predicted hydrogen bond with the Arg599 side-chain from αD of its 
symmetry mate. Interestingly, many of the residues involved in intramolecular and 
intermolecular interactions in the TrkA KID-hinge region including Arg593, Arg599, Lys609, 
Leu611, Glu615, Asp616, and Ala618 (human TrkA numbering) are replaced by different 
amino acids in TrkB (Tables 3.3, 3.4, 3.5). The TrkB KID loop is also shorter by two 
amino acids compared to the TrkA KID loop. These sequences differences in TrkB may 
contribute to the TrkB KID loop being displaced in the inactive TrkB TKD crystal 
structure (PDB ASZ) by the TrkB C-terminal tail and thus is in a different conformation 
than the TrkA KID loop (Figure 3.18).  
Comparing the TrkB and TrkA TKD structures that are now available in the PDB also  
reveals slight shifts in the position of key elements – notably for the P-loop and αC helix, 
which are both relatively shifted towards the C–lobe in the TrkA TKD structures. The 
movements are subtle, and could just be the result of crystal packing. However, as 
shown in Figure 3.18, the αC helix in TrkA-TKD (cyan) is shifted ~18° towards the C-
lobe compared to αC of TrkB-TKD (magenta). As a result the entire N-lobe of TrkA-TKD 
is shifted ~13° towards its C-lobe (Figure 3.18).  This shift of the TrkA-TKD N-lobe is 
noticeable in all of the now-available inactive TrkA-TKD structures (two without inhibitor 
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and one with inhibitor) and TrkB-TKD structures (one without inhibitor and three with 
inhibitor), which are shown overlaid in Figure 3.18.  
The intermolecular KID/hinge interactions seen in TrkA-TKD crystals (Figure 3.17) are 
not seen in any available TrkB-TKD structure.  TrkB-TKD does not form this dimer, and 
in any case, the KID loop of TrkB is in a distinct conformation due to displacement by the 
C-terminal tail of TrkB. The C-terminal tail of TrkB does not contact the hinge region or 
the β6-β7 loop as the KID does in the TrkA structures (Figure 3.18). Instead, the C-
terminal tail makes various contacts with the displaced KID loop and the lip of the 
activation loop of a symmetry mate. 
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Figure 3.16. TrkA-TKD intramolecular interactions not seen in TrkB-TKD.  
(A) The TrkA TKD (PDB 4F0I, chain A) inactive structure reported by Bertrand et al. in 
cartoon representation. KID/hinge intramolecular interactions they reported are boxed. 
(B) Close up of KID/hinge intramolecular interactions illustrating that Glu615 and Asp616 in 
the KID of TrkA interact with Arg593 and His594 in the hinge region, respectively. For 
consistency, all TrkA sequence numbering refers to human isoform ΙΙ and also used in 
PDB 4GT5. 
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Figure 3.17. TrkA-TKD dimer interface in two TrkA-TKD structures.  
The TrkA-TKD KID/hinge dimer interface shown in surface and cartoon representation. 
(A) Surface representation of the KID/hinge dimer in 4GT5 and chain A of 4F0I (4F0I-A). 
Note that the N-lobe of the monomer colored grey is headed into the plane of the page. 
(B) In the same orientation as the surface representation, cartoon representation is 
shown of the same dimer for 4GT5 and 4F0IA. (C) A close-up view of the KID/hinge 
region (boxed area in B) is shown for 4GT5 and 4F0I-A. Intermolecular and 
intramolecular interactions are shown. The residues involved in common interactions 
observed in both inactive structures are labeled. Note that the interfaces share many of 
the same interactions, but there are subtle differences due to the interface in 4GT5 being 
symmetric and the interface in 4F0I being asymmetric. Chain B of 4F0I is omitted from 
this figure for clarity, but the interactions of chain B are listed in Tables 3.3 and 3.4 along 
with a full list of interactions shown in this figure. 
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Figure 3.18. Comparison of TrkA and TrkB inactive TKD structures.  
(A) Overlay of the two inactive TrkA-TKD (cyan) structures without inhibitor (4GT5 and 
4F0I) with the TrkB-TKD (magenta) structures without (4ASZ) or with (4AT4 and 4AT5) 
inhibitor. Notice the shift of αC and N-lobe towards the C-lobe of the TrkA-TKD 
structures. This shift corresponds to ~18° and ~13° for αC and N-lobe between the TrkA 
(4GT5) and TrkB (4ASZ) TKD structures. On the right, the structures are rotated 45° out 
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of the plane of the page as shown, to illustrate the different conformation of the KID loop 
in TrkA and TrkB. (B) In the same orientation as the right side of part A, a surface 
representation of inactive TrkA-TKD (4GT5) is shown in grey, with cartoon 
representation of the TrkA KID (4GT5 and 4F0I) detailed in cyan. The TrkB KID and C-
terminal tail (from 4ASZ, 4AT4, and 4AT5) are shown in magenta in cartoon 
representation. Even though the N-lobe and αC of the inhibitor bound TrkA-TKD 
structure (4AOJ) superimposes well with the other TrkA structures, it is omitted from this 
figure because of a disordered activation loop and KID. Also omitted is one of the TrkB 
inhibitor bound structures (4AT3) because of unique P-loop and activation loop 
conformations that are probably due to the presence of inhibitor. 
 
Table 3.3. KID/hinge region intermolecular interactions. Summary of the KID/Hinge 
dimer interface interactions in the inactive TrkA TKD structures (PDB 4GT5 and PDB 4F0I). The 
two molecules in the 4F0I structure are designated 4F0I-A (chain A) and 4F0I-B (chain B). 
Sequence numbering refers to numbering from 4GT5. Residues highlighted are different in the 
TrkB TKD sequence. 
Molecule in A.U. Symmetry Mate    
Residue Location Residue Location 4GT5 4F0I-A 4F0I-B 
Trp514 β1 Gly614 KID X   
Tyr591 Hinge Gly614 KID X  X 
Tyr591 Hinge Glu615 KID  X  
Arg593 Hinge Glu615 KID X  X 
Arg599 αD Leu611 KID X X X 
Asp607 KID Lys609 KID  X  
Leu611 KID Arg599 αD X X X 
Gly614 KID Trp514 β1 X X  
Gly614 KID Tyr591 Hinge X X  
Glu615 KID Arg593 Hinge X X  
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Table 3.4. KID/hinge region intramolecular interactions. Summary of interactions of the 
KID/hinge region within a monomer in the inactive TrkA TKD structure (PDB 4GT5 and PDB 
4F0I). The two molecules in the 4F0I structure are designated 4F0I-A (chain A) and 4F0I-B (chain 
B). Sequence numbering refers to numbering from 4GT5. Residues highlighted are ones that are 
not present or different in the TrkB sequence. 
Residue Location Residue Location 4GT5 4F0I-A 4F0I-B 
Arg599 αD His594 Hinge   X 
His604 KID Ala618 KID  X X 
Glu615 KID Arg593 Hinge  X X 
Asp616 KID Arg593 Hinge X   
Asp616 KID His594 Hinge X X X 
Asp616 KID Gly661 β6- β7 loop X X X 
Asp616 KID Gln660 β6- β7 loop    
Gln660 β6- β7 loop Arg593 Hinge  X  
 
 
Table 3.5. KID/hinge region amino acid differences between TrkA and TrkB.  
TrkA TrkB Location 
Trp514 Arg558 β1 
Arg593 Lys637 Hinge 
Arg599 Lys643 αD 
Lys609 Val653 KID 
Leu611 Met655 KID 
Glu615 Asn659 KID 
Asp616 - KID 
Ala618 Pro660 KID 
Gln660 Glu702 β6- β7 loop 
Gly661 Asn703 β6- β7 loop 
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3.9.  TrkA mutant slows down the progression of TrkA-TKD 
autophosphorylation 
	  
The structural observations outlined above prompted us to hypothesize that the 
dimerization interface seen in crystal structures of TrkA-TKD (but not TrkB-TKD) may 
play a role in the enhanced TrkA-TKD autophosphorylation rate, and the concentration 
dependence of its activation.  To test this hypothesis, I used site-directed mutagenesis to 
mutate part of the TrkA KID loop to the corresponding residues seen in the TrkB KID 
loop. Figure 3.19 shows an alignment of TrkA, TrkB, and the TrkA KID mutant. Note that 
this TrkA-TKD KID mutant now has a shorter KID loop (by 2 residues), and lacks Glu615 
and Asp616, which are central in intermolecular and intramolecular interactions 
respectively in the TrkA-TKD KID/hinge dimer, as discussed above (Table 3.3 and 3.4).  
To examine the functional consequences of these KID mutations, I employed a 
radioactive autophosphorylation assay to monitor the autophosphorylation profile for 
TrkA, TrkA KID, and TrkB TKDs. As shown in Figure 3.20A, the TrkA and TrkB TKDs 
again differed in their rates of autophosphorylation. Furthermore, the TrkA KID mutant 
does display a slightly slower rate of autophosphorylation than wild-type TrkA-TKD, but 
is not reduced to the rate seen for TrkB-TKD autophosphorylation. A paired t test was 
performed for each time point to determine significant differences in the 
autophosphorylation profiles between TrkA, TrkA KID, and TrkB TKDs. Significant 
differences occur from 0.75 minutes to 3 minutes (Figure 3.20B), with the largest 
differences between TrkA, TrkA KID, and TrkB occurring in the earlier time points. This 
time region corresponds to the lag phase of the autophosphorylation profile observed in 
Figure 3.11 and 3.12. The data from these autophosphorylation experiments were also 
plotted to determine what is the time taken for TrkA, TrkA KID, and TrkB TKDs to reach 
half maximal autophosphorylation. These plots, along with the statistical significance of 
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the values obtain for half maximal autophosphorylation, are shown in Figure 3.22. As 
expected, TrkA-TKD reaches half maximal autophosphorylation faster than TrkA KID 
and TrkB TKDs. Thus, the TrkA KID mutant does appear to reduce TrkA TKD 
autophosphorylation to some extent, but autophosphorylation of the TrkA KID mutant 
remains significantly more rapid than that seen for TrkB-TKD. 
Taken together, these data are consistent with the crystallographically observed TrkA-
TKD dimer interface playing some role in the accelerated autophosphorylation of TrkA-
TKD – since mutating part of this interface does significantly disturb TrkA-TKD 
autophosphorylation. However, the effect is clearly only partial, possibly because we did 
not fully abolish dimerization with the KID mutations made. Indeed, according to the 
crystal structures there are other interactions in the crystallographic dimer interface that 
might also play an important role. There may also be other phenomena causing TrkA-
TKD to autophosphorylate faster. Another plausible explanation for a more transient lag 
phase for TrkA-TKD autophosphorylation is that autophosphorylation of TrkA-TKD itself 
may promote dimerization, which in turn would further promote autophosphorylation in 
an effective positive feedback loop.  Indeed, we have observed phosphorylation-
enhanced dimerization of the EGFR intracellular region, providing a possible precedent 
for such an effect (Sung Hee Choi, unpublished observations). 
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Figure 3.19.  Alignment of TrkA, TrkA KID mutant and TrkB in the KID region.   
This alignment illustrates how part of the KID loop involved in the TrkA-TKD dimer 
interface was replaced with residues from the TrkB KID loop. The magenta box below 
the sequences designates the KID loop. 
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Figure 3.20. Perturbations of the autophosphorylation profile of the TrkA-TKD KID 
mutant.  
(A) Radioactive autophosphorylation assays at RT with 4 µM of TrkA-TKD, TrkA KID-
TKD, or TrkB TKD protein (B) Histogram plot of relative moles of phosphate incorporated 
per mole of enzyme for time points from 0 to 5 minutes. A paired t test was used to 
compare data obtained with TrkA (n=3), TrkA KID (n=2), and TrkB TKDs (n=2), to 
determine statistical significance of differences with significance (P < 0.05) denoted with 
an asterisk. 
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Figure 3.21. Comparison of the time to the half maximal level of TKD 
autophosphorylation.  
(A) Data from Figure 3.20 were replotted and fit with a four-parameter logistic equation 
to obtain time to half maximal autophosphorylation. Curves were fit to the 0 to 30 minute 
data (inset), but only the data from 0 to 10 minute are shown for clarity. (B) Histogram of 
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the time to half maximal autophosphorylation for TrkA, TrkA KID, and TrkB TKDs. A 
paired t test was used to determine statistical significance (P < 0.05) denoted as an 
asterisk. 
 
 
3.10. Phosphorylation of TrkA-TKD may promote its self-association 
	  
To investigate further whether phosphorylated TrkA dimerizes, I produced 
phosphorylated TrkA (pTrkA) and mock treated TrkA (mTrkA) TKDs, the latter having 
been treated as if to fully phosphorylate the protein, except for the omission of ATP. Both 
pTrkA and mTrkA TKDs were then purified by size exclusion chromatography (SEC). 
The chromatogram from SEC revealed that pTrkA TKD elutes earlier than mTrkA TKD, 
indicating a higher molecular weight or spatial extent for the pTrkA species (Figure 
3.22). However, preliminary results with pTrkB and mTrkB TKDs also showed a similar 
elution pattern.  Both pTrkA and pTrkB TKDs may have an exposed region 
(phosphorylated activation loop, perhaps) of the TKD creating an increase in shape 
leading to both pTrkA and pTrkB TKDs eluting earlier.  
I next used sedimentation equilibrium (SE) analytical ultracentrifugation (AUC) in an 
effort to determine whether pTrkA-TKD dimerizes weakly. The pTrkA and mTrkA TKD 
samples described above were each loaded at a concentration of 16.7 µM and 
sedimented at various speeds. A difference in sedimentation was observed between 
mTrkA and pTrkA TKDs, as shown in Figure 3.23. The AUC data were analyzed by 
plotting the logarithm (ln) of absorbance at 280 nm versus the radius squared (r
2
-ro
2
)/2. 
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The slopes of the linear fits of the data were used to calculate the apparent masses of 
mTrkA and pTrkA TKDs. A difference of ~6 kDa was observed between the calculated 
masses of mTrkA and pTrkA TKD species, consistent with a weak self-association of 
pTrkA-TKD. 
 
 
Figure 3.22. Difference in size exclusion chromatography profiles between mTrkA 
and pTrkA TKDs.  
Size exclusion chromatography (SEC) profiles of mTrkA-TKD (black line), pTrkA-TKD 
(red line) and standards (grey dashed line). The molecular weight of the standards 
(BioRad) in kDa is listed above each standard peak. Preliminary results indicate a similar 
elution pattern for pTrkB and mTrkB TKDs. 
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Figure 3.23. Sedimentation equilibrium analytical ultracentrifugation experiments 
with mTrkA and pTrkA TKDs.  
Sedimentation equilibrium analytical ultracentrifugation experiments were performed with 
16.7 µM of pTrkA-TKD and 16.7 µM of mTrkA-TKD to assess whether there is any 
difference in behavior of these two species in solution. To analyze the data, we 
generated a plot of the natural logarithm (ln) of absorbance at 280 nm versus the radius 
squared (r
2
-ro
2
)/2, where r is the radial position in the sample and ro is the radial position 
of the meniscus. For a single species, this analysis provides a straight line with slope 
proportional to the molecular mass of that single species (or weight average molecular 
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weight of multiple species). Data collected at 10,000 rpm (A) and 15,000 rpm (B) both 
show a difference of ~6 kDa between the calculated masses of mTrkA and pTrkA TKDs. 
 
 
3.11. Conclusions 
	  
TrkA and TrkB are homologous RTKs that are thought to initiate similar signaling 
pathways upon ligand-induced activation of their TKDs. However, various reports have 
demonstrated that TrkA and TrkB expression and activation result in quite distinct 
cellular outcomes when TrkA and TrkB are expressed in the same cell type. The 
different outcomes appear to be correlated with sustained activation of the Erk pathway 
when TrkA is engaged by its ligand (leading to differentiation) and by more transient 
activation of the Erk pathway when receptors such as TrkB, EGFR, and IR are activated 
by their ligands (leading to proliferation, at least in the case of PC12 cells).  Thus, it 
appears that the difference in signaling specificity may arise not from activation of 
different signaling components per se, but from different kinetics of activation – likely 
with the engagement of different positive and/or negative feedback elements in the 
pathway.  Recent reports demonstrated that homologous kinases in the same family 
may have different intrinsic kinase activities and activation kinetics (Joseph et al., 2013; 
Latour et al., 1996; Lew et al., 2007). Furthermore, previous studies have demonstrated 
that the strength of an initiating signal from an RTK can dictate the cellular response 
(Dikic et al., 1994; Traverse et al., 1994). Therefore, we sought to determine whether 
there is an intrinsic difference between the TKDs of TrkA and TrkB that may underlie the 
distinct cellular responses downstream of TrkA and TrkB activation.  
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We show that the isolated TrkA TKD autophosphorylates faster than TrkB TKD.  This 
faster autophosphorylation rate cannot be explained by differences in the order of 
autophosphorylation site usage. The TrkA and TrkB TKDs appear to have similar 
intrinsic kinase activities, raising the question of what is the source of the difference in 
autophosphorylation rates. Notably, TrkB-TKD autophosphorylation has a non-linear lag 
phase that was not present in TrkA-TKD. Previous reports have characterized a non-
linear phase of TrkB autophosphorylation (Iwasaki et al., 1997). The authors concluded 
that the non-linear phase is the result of slow cis phosphorylation that occurs prior to 
trans phosphorylation. However, the dominant result observed in those experiments was 
trans phosphorylation. The cis phosphorylation described by the authors only occurred 
during conditions with very low concentrations of ATP. Furthermore, the reaction 
conditions are very different from the conditions used in this study. Most importantly, 
Iwasaki et al. were using ng/µl concentrations of full length TrkB intracellular domain with 
20 µM to 100 µM of ATP in the presence of MnCl2 instead of MgCl2 (Iwasaki et al., 
1997). 
To address the difference of autophosphorylation between TrkA and TrkB TKDs, we 
describe a unique TrkA-TKD crystallographic dimer that is not observed in the TrkB-TKD 
structures. We used site directed mutagenesis to disrupt this dimer and show that these 
mutations do have a minor effect on slowing autophosphorylation when compared to WT 
TrkA-TKD.  The fact that the effect is modest may reflect incomplete disruption of the 
dimer, or may suggest (as we suspect is likely) that additional mechanism also 
contribute to the faster rate of TrkA-TKD autophosphorylation. Indeed, our data further 
suggest that phosphorylation of TrkA-TKD may also promote dimerization, suggesting 
that the elevated rate of TrkA-TKD autophosphorylation compared to TrkB-TKD may be 
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caused in part by TrkA self-association.  Such a self-association, phosphorylation-
induced mechanism could promote a stronger and more sustained TrkA-mediated signal 
in the cell when TrkA is activated. Indeed, an autophosphorylation-induced activation of 
an RTK would constitute a positive feedback loop, which is exactly what would be 
required for the switch-like sustained response seen with TrkA differentiative signaling. A 
similar phenomenon, although not yet defined in molecular terms, has also been 
observed in vitro for the EGFR intracellular domain (unpublished).  Further cellular 
studies are needed to test whether this TrkA-TKD self-association may play a role in 
dictating the nature and kinetics of the cellular response seen upon TrkA activation by its 
ligands. 
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Chapter 4:   
Conclusions and future directions 
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4.1.  Conclusions 
	  
The similar activation loop conformation of many of the IRK TKD family members 
suggests that these kinases utilize the same autoregulatory mechanisms. As discussed 
in Chapter 2, there is a subset of IRK TKD family members that have a different 
activation loop conformation and these kinases possess a different autoregulatory 
mechanism. Analysis of the reported cancer related mutations of the IRK TKD family 
members clearly demonstrates that mutations occur more frequently or over a wider 
range of residues in IRK TKD family members that do not utilize pseudosubstrate 
inhibition, whereas the IRK TKDs that employ pseudosubstrate inhibition have very few 
reported cancer mutations. Instead, some of the RTKs in the IRK TKD family (IR, IGF1R, 
Trk) that use pseudosubstrate inhibition show altered expression in cancer more often 
(or rather) than mutations (Belfiore and Malaguarnera, 2011; Davidson et al., 2003; 
Lagadec et al., 2009; Larsson et al., 2006; Tanaka et al., 2009). Indeed, many of the 
initially reported TrkB cancer mutations present in the activation loop have now been 
shown not to be gain of function mutations (Harada et al., 2011).  
Altered or increased expression of an RTK can impact the signaling network in which it 
is embedded in a multitude of ways. Overexpression can overload receptor trafficking 
pathways, thus ultimately producing more receptors at the cell surface. However, in the 
case of PC12 cells, over expression of RTKs (EGFR and IR) and activation causes cells 
to differentiate. Altered and/or overexpression of an RTK could cause “novel” protein 
interactions that modulate and drive the network into a proliferative response. Proteomic 
approaches should be able to determine the existence of novel RTK-protein interactions 
that would dictate the signaling specificity. Along with proteomic approaches, I would 
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argue that a thorough and quantitative analysis of the kinetics of RTK activation is 
needed to understand and interpret the effect of RTK expression in a particular cell type.   
In Chapter 3, I address signaling specificity differences between activation of TrkA and 
TrkB.  TrkA and TrkB are very homologous proteins, yet activation and expression of 
each in neuroblastoma cells produces quite distinct cellular outcomes. It is noteworthy 
that neuroblastoma cells are of sympathetic origin and TrkA is known to play important 
roles in the development and maintenance of the sympathetic nervous system. On the 
contrary, TrkB is rarely expressed in the sympathetic nervous system. Thus, 
quantitatively understanding the kinetics of TrkA and TrkB activation is essential to 
fathom the resulting differences upon their expression and activation in neuroblastoma 
cells. Furthermore investigating the activation of TrkA and TrkB will provide insight into 
what are also other factors that shapes the signaling response in a particular cell type, 
for example the threshold of activation set by surrounding phosphatases. 
I show that indeed the activation of TrkA and TrkB could be distinct since TrkA TKD 
autophosphorylates itself faster than TrkB TKD and that this, in part, may be due to an 
increased self-association of the TrkA TKD. Upon TrkA activation by ligand binding, a 
self-association mechanism could promote a stronger and more sustained TrkA-
mediated signal in the cell. Indeed, a stronger ability to autophosphorylate and induced 
activation of an RTK could contribute to a sustained response seen with TrkA 
differentiative signaling. Further cellular studies are needed to test whether this TrkA-
TKD self-association and faster rate of autophosphorylation aids in shaping the 
downstream signaling network causing sustained Erk activation and cellular 
differentiation upon TrkA activation by its ligand. 
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There are reports that show that homologous protein-tyrosine kinases with distinct 
catalytic activities have specific roles in the cellular context in which they are normally 
expressed. For example, the members of the Tec family, Itk and Btk are soluble kinases 
exclusively expressed in T cells and B cells, and downstream of T cell and B cell 
receptor activation, respectively (Joseph et al., 2013). Joseph et al. demonstrated that 
Btk’s increase kinase activity (increase in kcat) is due to dynamics of its activation loop 
and an Itk chimera harboring Btk’s activation loop displays an increase in kinase activity 
(Joseph et al., 2013). Importantly, this Itk chimera changed the shape of the signaling 
network in T cells to a sustained cellular signal. Differences in intrinsic kinase activity 
have also been shown between ZAP-70 and Syk, members of the Syk family of 
nonreceptor protein-tyrosine kinases that are expressed in distinct hemopoietic cells 
(Latour et al., 1996).  
These examples along with the data presented in this dissertation suggest that kinase 
activity is an imporatant component of the signaling network in which that particular 
kinase is embedded. The type of difference of kinase activity (increase kcat) within the 
Tec and Syk families could undoubtedly be distinct from any differences within an RTK 
family since each is uniquely embedded (receptor compared to soluble tyrosine kinase) 
in the signaling network.  
Quantitatively understanding the kinase activity at various levels of the network will be 
fruitful in understanding the spatial threshold set by phosphatase. In particular, studies 
need to be performed in various cell lines to determine if cell specific responses of 
expressing and activating a RTK is determined by a quantitative relationship between 
kinase activity compared to the surrounding phosphatase.  
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4.2.  Future Directions 
	  
The work described in this dissertation provides a foundation for future biochemical and 
structural studies of the Trk family. The autoinhibitory mechanism utilized by the Trk 
TKDs is similar to IRK and involves pseudosubstrate autoinhibition by the activation 
loop. Further structural and biochemical studies of Trk intracellular domain (ICD) 
constructs that include the juxtamembrane region would be insightful in fully 
understanding the regulatory mechanisms of the Trk family.  In the case of TrkA, 
mutation of the single JM tyrosine in TrkA to phenylalanine had little effect on 
autophosphorylation (Obermeier et al., 1994; Stephens et al., 1994), whereas mutation 
of the corresponding JM tyrosine to phenylalanine in TrkB did diminish 
autophosphorylation in cell-based assays (Minichiello et al., 1998; Postigo et al., 2002).  
The full-length ICD constructs tend to have poor expression, but now that the 
experimental framework is established it should be feasible to obtain enough protein to 
determine the influence (if any) of the juxtamembrane region of TrkA and TrkB on the 
kinase activity and autophosphorylation in vitro.  
I have shown that the isolated TrkA TKD autophosphorylates itself faster than its TrkB 
counterpart and this may be due in part to TrkA-TKD self-association that is not 
observed for TrkB.  Further analytical ultracentrifugation studies are needed to 
thoroughly investigate the characteristics of TrkA-TKD self-association. It will be 
interesting to perform these studies under various conditions to determine if binding of 
ATP or inhibitor influences TrkA self-association. Performing analytical 
ultracentrifugation studies with the TrkA KID mutant will also be informative to determine 
whether the mutations studied hinder TrkA-TKD self-association. Further mutations to 
disturb the crystallographic dimer interface would also aid in characterizing the residues 
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important for TrkA-TKD self-association. Analytical ultracentrifugation experiments with 
phosphorylated TrkB-TKD and mock treated TrkB-TKD need to be conducted to truly 
determine if phosphorylation promoting dimerization is exclusively occurring in TrkA or if 
it is a more general phenomenon.  If it is a more general phenomenon, further 
characterizing the TrkA KID/hinge region interactions role on autophosphorylation will be 
key in understanding the intrinsic differences between the TrkA and TrkB TKDs. 
The studies in this dissertation were performed with soluble TrkA and TrkB TKDs. To 
mimic ligand-induced RTK dimerization, the histidine-tagged TrkA and TrkB TKD should 
be clustered (via its histidine tag) on the surface of small unilamellar vesicles containing 
lipid molecules with a nickel-nitrilotriacetate head group (Ni-NTA DOGS). This approach 
has been shown to mimic ligand-induced activation for the EGFR TKD (Zhang et al., 
2006) and ALK (Bresler et al., 2011). TKD clustering on the surface of the Ni-NTA-
containing vesicles promotes trans-autophosphorylation (and thus activation), and has 
also been shown for EGFR (Zhang et al., 2006) to drive allosteric components of 
dimerization-induced activation. Autophosphorylation assays of TrkA and TrkB TKDs 
that are clustered on lipid vesicles will begin to determine the physiological significance 
of differences in autophosphorylation.  
A vital next step in this project is to determine the significance of the faster TrkA-TKD 
autophosphorylation and ligand-independent TrkA self-association in cells. The best 
approach for the cell experiments would be to generate chimeric receptors containing 
the extracellular region of PDGFR and either the TrkA or TrkB intracellular domain to 
truly investigate the role of the intracellular domain including the TKD in defining the 
difference between TrkA and TrkB signaling. This approach would allow for expression 
matching which will be vital for interpreting any result (see below). Thus, once the proper 
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cells system is established, it will be essential to first validate the rate difference in 
autophosphorylation of TrkA and TrkB in cells. Introducing TrkA KID/hinge region 
mutations in the cellular context will be very informative to measure the 
autophosphorylation and downstream signaling response. 
These cell culture experiments may prove to be difficult because the cell type chosen will 
greatly affect the results. These experiments should be conducted in several cell types, 
starting with neuroblastoma cell lines as well as PC12 cells since there is a wealth of 
knowledge regarding the signaling network in these contexts.  Furthermore, PC12 cells 
can behave like sympathetic neurons when subjected to NGF and this may due to the 
fact that chromaffin cells (the cell type PC12 originate from) are derived from the same 
neural crest progenitor as sympathetic neurons (Greene 1976). However, TrkB is not 
normally expressed in PC12 cells and expressing TrkB and activating it in PC12 does 
lead to differentiation. This result could simply be due to overexpressing TrkB and not 
obtaining the level of TrkB needed for a proliferative response. Previous reports have 
shown that overexpressing EGFR and IRK converts the normal proliferative response 
upon activation of EGF and insulin into a differentiative response. Thus, expression 
levels of TrkA and TrkB need to be carefully matched in all future cell experiments. 
The above-mentioned biochemical and structural experiments along with the cellular 
experiments will be instrumental to truly understand the origin of signaling differences 
between TrkA and TrkB expression and activation. Furthermore, a deeper quantitative 
understanding and how it relates to the TrkA and TrKB signaling differences in the 
cellular context will be required for safe and specific therapies targeting TrkA or TrkB.  
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Chapter 5:  
Materials and Methods. 
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5.1. Plasmid Construction 
	  
DNA encoding the intracellular domain residues 498-796 of human TrkA (NCBI 
reference sequence NM_002529.3) and residues 542-838 of human TrkB (NCBI 
reference sequence XP_005252001.1) were amplified by PCR to include a coding 
sequence for an N-terminal hexahistidine tag and unique EcoRI and XhoI restriction 
sites for TrkA and TrkB. Residues 452-753 of human Ror2 (NCBI reference sequence 
NM_004560.3) was also amplified by PCR to include a coding sequence for an N-
terminal hexahistidine tag and unique SpeI and XhoI restriction sites for Ror2.  
Appropriately digested fragments were subcloned into the pFastBac1 vector (Invitrogen) 
using the indicated restriction sites.  The Bac-to-Bac expression system (Invitrogen) was 
then used for generation of recombinant baculoviruses and for protein expression in 
Spodoptera frugiperda Sf9 cells.  
 
5.2. Protein Production and Purification 
	  
Sf9 cells at 1.5-2 x 106/ml were infected with recombinant baculovirus, and harvested by 
centrifugation after 3 days.  Sf9 cells expressing histidine-tagged TrkA498-796 (~7 liters of 
medium) were lysed by sonication in 100 ml of 50 mM NaKPO4, pH 8.0, containing 300 
mM NaCl, 5% glycerol, 10 mM imidazole, 10 mM 2-mercaptoethanol, 0.5 mM PMSF and 
protease inhibitor cocktail (Roche).  The lysate was then mixed with Ni-NTA beads 
(Qiagen) for 1 hour at 4°C.  Beads were washed in 50 column-volumes of lysis buffer 
(described above), and bound TrkA-TKD was eluted with increasing concentrations of 
imidazole in 25 mM MES, pH 6, containing 300 mM NaCl, 5% (w/v) glycerol, 10 mM 2-
mercaptoethanol, 0.5 mM PMSF and protease inhibitor cocktail (Roche).  Eluted protein 
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was then further purified using a Fractogel SO3- cation exchange column (EMD) 
equilibrated with 25 mM MES, pH 6, containing 5% glycerol, 2 mM DTT and eluting with 
a gradient from 10 mM to 1 M NaCl.  TrkA was then applied to a HiTrap Butyl Sepharose 
HP column (GE Healthcare) in 25 mM MES, pH 6, containing 150 mM NaCl and 2 mM 
DTT, eluting with a gradient from 0.8 M to 0 M (NH4)2SO4, and subjected to a final step 
of size exclusion chromatography using a Superdex 200 column (GE Healthcare) 
equilibrated in 25 mM MES, pH 6, containing 250 mM NaCl and 2 mM DTT. 
 
Sf9 cells expressing histidine-tagged Ror2 TKD (~8 liters of medium) were lysed by 
sonication in 150 ml of lysis buffer, composed of 20 mM NaKPO4, pH 8.0, containing 200 
mM NaCl, 10 mM 2-mercaptoethanol, 1 mM PMSF, 10 µM benzamidine, 2.3 µM 
leupeptin, 2 µM aprotinin, and 3 µM pepstatin (Sigma).  Cell lysates containing Ror2 
TKD protein were mixed with Ni-NTA beads (Qiagen) for 30 minutes at 4°C, which were 
then washed with lysis buffer prior to elution of protein in lysis buffer containing 200 mM 
imidazole.  Eluted protein was passed through a Fractogel TMAE column (EMD) 
equilibrated with 25 mM Tris-HCl, pH 8, containing 100 mM NaCl and 2 mM DTT to 
remove anionic contaminants, and was then passed through a CHT2.1 hydroxyapatite 
column (Bio-Rad) equilibrated in 20 mM HEPES, pH 8, containing 2.5 mM NaKPO4, 200 
mM NaCl, 2 mM DTT, and 1 mM PMSF, prior to loading on to a HiTrap Butyl Sepharose 
HP column (GE Healthcare) in 25 mM Tris-HCl, pH 8, containing 125 mM NaCl and 2 
mM DTT.  Ror2-TKD was eluted from butyl sepharose with a gradient from 0.5 M to 0 M 
(NH4)2SO4 in this same buffer, and then subjected to size exclusion chromatography 
using a Superdex 200 column (GE Healthcare) equilibrated in 20 mM Tris-HCl, pH 7.5, 
containing 120 mM NaCl and 1 µM TCEP. 
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The purification scheme described above for TrkA-TKD was used for the crystallization 
studies and initial autophosphorylation assays. However, the purification scheme was 
optimized for further studies of TrkA and TrkB TKDs due to heterogeneity of post 
translation modification and to ensure no phosphatase contamination. The cells were 
lysed and bound to Ni-NTA beads as described above for TrkA-TKD. However, the 
bound TrkA or TrkB TKD was eluted with increasing concentrations of imidazole in 50 
mM NaKPO4, pH8, containing 300 mM NaCl, 5% (w/v) glycerol, 10 mM 2-
mercaptoethanol, 0.5 mM PMSF and protease inhibitor cocktail (Roche).  Eluted protein 
was then further purified using a Fractogel SO3- cation exchange column (EMD) 
equilibrated with 25 mM MES, pH 6, containing 5% glycerol, 2 mM DTT and eluting with 
a gradient from 10 mM to 1 M NaCl.  TrkA and TrkB TKD proteins were concentrated to 
~ 5-6 mls and treated with YopH phosphatase at 2 µM for 1 hour at 30° in the presence 
of 1mM EDTA. Pilot experiments with YopH had lower activity at a higher pH an 
observation previously reported. Furthermore, EDTA was added during the phosphatase 
treatment since protein tyrosine phosphatase activity is not dependent on metals and in 
some cases metal ions can inhibit their activity. (Lu and Zhu, 2011; Zhang et al., 1992; 
Zhang, 2003). YopH was purified away using a Fractogel SO3- cation exchange column 
(EMD) equilibrated with 25 mM HEPES, pH 8, containing 5% glycerol, 2 mM DTT. YopH 
is highly basic and binds very effectively to the cation exchange column at pH 8 where 
as both TrkA and TrkB TKDs do not bind.  TrkA and TrkB TKD proteins were then 
concentrated to a volume of ~5-6 ml and treated with 2 µM λ phosphatase in the 
presence of 5 mM MnCl2 for 1 hour at 30°. Pilot experiments and previous reports 
showed greater activity of λ phosphatase at pH 8 and with MnCl2 (Barik, 1993; Zhuo et al., 
1993). λ phosphatase was purified away by using a Fractogel SO3- cation exchange 
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column (EMD) equilibrated with 25 mM MES, pH 6, containing 5% glycerol, 2 mM DTT 
and eluting with a gradient from 10 mM to 1 M NaCl.  TrkA or TrkB TKD was then 
applied to a HiTrap Butyl Sepharose HP column (GE Healthcare) in 25 mM MES, pH 6, 
containing 150 mM NaCl and 2 mM DTT, eluting with a gradient from 0.8 M to 0 M 
(NH4)2SO4, and subjected to a final step of size exclusion chromatography using a 
Superdex 200 column (GE Healthcare) equilibrated in 25 mM Hepes, pH 8, containing 
150 mM NaCl and 2 mM DTT. 
 
YopH BL21 cells were grown in 1 liter of LB with 50 µg/ml streptomyocin at 37°C until a 
density of ~0.6 OD600 nm. At that point, the cells were cooled down to 18°C and induced 
with 1mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and grown overnight. Cells were 
harvested by centrifugation at 2,000 x g for 15 minutes at 4°C. Cells were lysed by 
sonication in 50 mM Hepes, pH 7.4, 300 mM NaCl, 10% glycerol, 10 mM imidazole, 10 
mM 2-mercaptoethanol, 0.5 mM PMSF and protease inhibitor cocktail (Roche). Protein 
lysate was incubated with Ni-NTA beads (Qiagen) for 1 hour at 4°C and then washed 
with 20 mM imidazole prior to eluting with 300 mM imidazole. YopH was then loaded on 
to a Fractogel SO3- cation exchange column (EMD) equilibrated with 25 mM MES, pH 6, 
containing 5% glycerol, 2 mM DTT and eluting with a gradient from 10 mM to 1 M NaCl. 
Fractions corresponding to the peak were pooled, concentrated and loaded on to a size 
exclusion Superdex 200 column (GE Healthcare) equilibrated in 25 mM MES, pH 6, 
containing 250 mM NaCl and 2 mM DTT. 
λ phosphatase was expressed and purified essentially as described (Zhuo et al., 1993). 
However, the first purification step was phenyl-sepharose chromatography and not Bio-
Gel A chromatography. Instead, after the phenyl-sepharose column, the λ phosphatase 
fractions were pooled, concentrated and loaded on to a size exclusion (Superdex 200) 
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column (GE Healthcare) equilibrated in 25 mM Tris, pH 7.5, containing 150 mM NaCl. 
Purified λ phosphatase was stored at -80°C at 20 mg/ml in the buffer used for size 
exclusion chromatography plus a final concentration of 10% glycerol. 
 
5.3. Crystallization and Structure Determination 
	  
Crystals were obtained using the hanging drop vapor diffusion method, by mixing equal 
volumes of protein and reservoir solutions and equilibrating over the reservoir solution at 
21˚C.  For TrkA498-796 TKD, protein was concentrated to ~6 mg/ml in 25 mM MES, pH 6, 
containing 250 mM NaCl and 2 mM DTT and then diluted with water to 3.25 mg/ml.  
Crystals were obtained with a reservoir solution of 1.5 M NaCl, 0.1 M MES pH 6.5, and 
0.2 M Na/K phosphate.  For Ror2452-753, protein was concentrated to 7.2 mg/ml in 20 mM 
Tris-HCl, pH7.5, containing 125 mM NaCl, and 1 µM TCEP, and crystals were obtained 
over a reservoir containing 20% PEG3350 and 0.2 M Mg(NO3)2 (Hampton Research 
PEG Ion Screen 16).  Prior to flash freezing in liquid nitrogen, TrkA498-796 crystals were 
cryo-protected in reservoir solution containing 40 % (w/v) dextrose, and Ror2452-753 
crystals were cryo-protected in reservoir solution containing 20% (w/v) glycerol.  
Diffraction data were collected at beamline 23ID-B of GM/CA@APS (Advanced Photon 
Source) and were processed using HKL2000 (Otwinowski and Minor, 1997) (Table 1).  
TrkA498-796 crystallized in space group H32 with one molecule in the asymmetric unit, and 
Ror2452-753 crystallized in space group C2221 with 2 molecules in the asymmetric unit. 
 Structures were solved by molecular replacement with Phaser (Collaborative 
Computational Project, 1994), using coordinates for the MuSK tyrosine kinase domain 
(PDB 1LUF) (Till et al., 2002) as search model.  Cycles of manual building/rebuilding 
using Coot (Emsley and Cowtan, 2004) were alternated with rounds of refinement 
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employing REFMAC (Collaborative Computational Project, 1994), plus composite omit 
maps calculated with CNS (Brunger et al., 1998).  Later stages employed PHENIX 
(Adams et al., 2010), with TLS refinement (Winn et al., 2001).  PROCHECK (Laskowski 
et al., 1993) identified no residues in the disallowed region of the Ramachandran plot.  
Structure figures were generated using PyMOL (The PyMOL Molecular Graphics 
System, Version 1.5.0.4, Schrödinger, LLC). Data collection and refinement statistics are 
shown in Table 1. The final refined TrkA model includes amino acids 498-534, 537-548, 
550-610, and 614-793.  There is additional density close to the N-terminus of TrkA 
structure that we could not model confidently, projecting towards the active site.  The 
final Ror2 structure is missing density for residues 452-463 at the N-terminus.  In 
addition, residues 512, 516, 576-580, and 752-753 in chain A could not be confidently 
modeled, and nor could residues 515, 573-580, and 753 in chain B.  Cys694 in both chain 
A and chain B of the Ror2 TKD appears to form a disulfide bond with an equivalent 
residue in a symmetry mate. 
 
5.4. Circular dichroism 
	  
TrkA and TrkB TKD proteins were diluted to 2 µM into a buffer containing 25 mM 
NaH2PO4 K2HPO4 pH7.4, 150 mM NaCl. CD spectra and thermal melting curves were 
obtained on an Aviv 62A DS spectropolarimeter (Aviv Associates, NJ) with a 1 mm 
pathlength sample holder. The wavelength scan was performed at 1°C. The thermal 
melting curves were obtained by heating samples from 1°C to 97°C in 1°C increments 
with the circular dichroism at 222 nm being measured at each step. Mean residue 
ellipticity was determined using the formula MRE = θd*0.1*MRW/(d*c), where θd = 
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observed ellipticity (mdeg), MRW = mean residue weight (MW of protein/number of 
residues), d = pathlength in cm, c = concentration of protein in mg/ml. The K2D3 server 
was used to predict the helical and sheet composition of TrkA and TrkB TKDs (Louis-
Jeune et al., 2011).   
 
5.5. Sedimentation equilibrium analytical ultracentrifugation experiments 
	  
All sedimentation equilibrium (SE) analytical ultracentrifugation (AUC) experiments were 
performed at 4°C using a Beckman Coulter™ Optima XL-A instrument. Initial SE AUC 
experiments to assess protein aggregation were performed with 16.7 µM of TrkA-TKD 
and 17.6 µM of TrkB-TKD. The TrkA-TKD sample for AUC was not treated with 
phosphatases during purification where as the TrkB-TKD sample was treated with 
phosphatases during purification. Data shown were collected at 10,000 rpm. To assess 
the behavior of pTrkA-TKD and mTrkA-TKD in solution, SE AUC experiments were 
performed with 16.7 µM of pTrkA-TKD and 16.7 µM of mTrkA-TKD. Data were collected 
at 10,000 rpm and 15,000 rpm. 
To analyze the data, we generated a plot of the natural logarithm (ln) of absorbance at 
280 nm versus a function of the radius squared (r
2
-ro
2
)/2, where r is the radial position in 
the sample and ro is the radial position of the meniscus. This analysis provides a straight 
line with slope proportional to the molecular mass for a single species. 
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5.6. Autophosphorylation Assays  
	  
All autophosphorylation reactions were conducted in the presence of 1 mM ATP (Sigma-
Aldrich) and 10 mM MgCl2 in a buffer containing 100 mM HEPES pH 7.4, 150 mM NaCl, 
2 mM DTT and 1x ‘Halt’ phosphatase inhibitor cocktail (Thermo Scientific #1862495), 
which contains sodium fluoride, sodium orthovanadate, sodium pyrophosphate, and β-
glycerophosphate. Figure legends indicate the concentration of TrkA and TrkB TKD 
proteins, which ranged from 1 to 10 µM and indicate the temperature the reactions were 
incubated which ranged from 15°C -37°C. The autophosphorylation reactions were 
analyzed by various gel-based methods including native PAGE, SDS-PAGE 
autoradiography, SDS-PAGE Western blotting, and PhosTag SDS-PAGE. The 
autophosphorylation reactions analyzed by native PAGE and SDS-PAGE 
autoradiography did not contain 1x Halt phosphatase inhibitor cocktail unless indicated 
in the figure legend. For the phosphatase inhibitor comparison experiment, ‘PhosStop’ 
inhibitor cocktail inhibitor (a proprietary blend of phosphatase inhibitors) was purchased 
from Roche. 
 
5.7. Gel based Assays 
	  
Native PAGE was conducted following the Laemmli protocol (Laemmli, 1970), except 
that SDS was not included in the gel or electrophoresis buffers. Thus, samples were 
separated on a 7.5 % native gel with a pH 6.8 Tris-HCl stacking gel and a pH 8.8 Tris-
HCl resolving gel. The electrophoresis running buffer used was a Tris-glycine pH 8.8 
buffer. Gels were stained at room temperature with Coomassie brilliant blue R-250. 
Coomassie stained native gels were imaged on a Kodak Image Station 440 CF.  
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Autoradiographs and Coomassie gels were used to monitor a time course of TrkA and 
TrkB autophosphorylation. Samples were separated on a 12.5% Laemmli gel by SDS-
PAGE, gels were stained at room temperature with Coomassie brilliant blue R-250, 
destained and then dried using a gel dryer (Thermo electron corporation). Dried gels 
were applied to a storage phosphor screen for overnight exposure.  Phosphor screens 
were then imaged using a Storm 820 phosphorimager (Molecular Dynamics®). The 
autoradiography signal was normalized by the amount of protein in each lane detected 
by Coomassie stain. 
For SDS PAGE Western blotting, samples were separated on a 12.5% Laemmli gel, 
transferred to nitrocellulose and then blocked with blocking buffer (LI-COR Biosciences 
blocking buffer diluted 1:2 with PBS). Membranes incubated with primary antibody 
diluted in blocking buffer overnight at 4°C, washed with PBS with 1% Tween, and then 
incubated with secondary antibody diluted in blocking buffer. Membranes were washed 
with PBS with 1% Tween and then subjected to a final wash with just PBS. Membranes 
were imaged using the Odyssey® FC (LI-COR Biosciences) imaging station. 
PhosTag gels were made using the PhosTag™ acrylamide reagent (Wako Pure 
Chemical Industries, Ltd., catalog # AAL-107) along with ZnCl2 as previously described 
(Kinoshita and Kinoshita-Kikuta, 2011)). The composition of reagents for optimal 
separation of phosphorylated Trk TKD species was 25 µM PhosTag™ acrylamide 
reagent and a 10% acrylamide gel using acrylamide:bis solution (29:1). Gels were run at 
a constant 70V for 3 hours. PhosTag gels were stained at room temperature for ~15-20 
minutes with Coomassie brilliant blue R-250. For Western blotting, prior to transferring to 
nitrocellulose, PhosTag gels were soaked in transfer buffer containing 1mM EDTA for 15 
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minutes and then washed for 15 minutes in transfer buffer without EDTA. The rest of the 
Western blot protocol was performed as described above. 
For Western blotting, the goat anti-pan-Trk antibody (catalog number: sc-11-g) and 
rabbit anti-phospho-Trk pY676 (catalog number: sc-130222) antibodies were used at a 
1:500 dilution and are from Santa Cruz. The rabbit anti-phospho Trk pYY680/681 
(catalog number: 4621)) and rabbit anti-pY791 (catalog number: 4168) were used at 
1:1000 dilution. Note that the Cell Signaling phospho antibodies are sold using the TrkA 
isoform I numbering, thus pYY674/675 and pY785 corresponds to pYY680/681 and 
pY791 in isoform II, respectively. The secondary antibodies used were IRDye® 800CW 
donkey anti-rabbit IgG (# 926-32213) and IRDye® 680RD donkey anti-goat IgG (# 926-
68074) from LI-COR Biosciences. 
The normalized relative signals from the Western blots were determined first by 
normalizing each phosphospecific signal with the total Trk signal. Each normalized 
signal was then divided and by the maximum signal per phosphospecific antibody per 
reaction. 
 
5.8 Generation and purification of phospho-Trk TKD 
	  
Autophosphorylation reactions were conducted to generate phospho-Trk for enzymatic 
studies. Western blotting of PhosTag gels with phosphospecific antibodies (see Western 
blotting methods) were used to monitor the reactions. TrkA-TKD at 10 µM was incubated 
at room temperature with 1 mM ATP, 10 mM MgCl2 in a buffer containing 100 mM 
HEPES pH 7.4, 150 mM NaCl, 2 mM DTT. At 5 minutes, the reaction was quenched with 
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EDTA to achieve a final concentration of 100mM. TrkB-TKD at 7.5 µM was incubated at 
30°C with 1 mM ATP, 10 mM MgCl2 in a buffer containing 100 mM HEPES pH 7.4, 150 
mM NaCl, 2 mM DTT and 1x Halt phosphatase inhibitor cocktail. At 4 minutes, the 
reaction was quenched with EDTA to achieve a final concentration of 100mM. Samples 
were spin filtered with SpinX columns and loaded on to a Superdex 200 column (GE 
Healthcare) equilibrated in 25 mM Hepes, pH 8, containing 150 mM NaCl and 2 mM 
DTT and 1x Halt phosphatase inhibitor cocktail. BioRad gel filtration standards (# 151-
1901) were used to assess pTrk and mTrk TKD elution peaks. 
 
5.9. Quantitative kinase assays 
	  
The quantitative kinase assays employed a peptide mimic of the TrkA and TrkB 
activation loop. The TrkA activation loop peptide (SRDIYSTDYYRVGGRTMLPIR) and 
TrkB peptide (SRDVYSTDYYRVGGHTMLPIR) were purchased from CanPeptide. 
Reactions were performed at room temperature in a buffer containing 100 mM HEPES 
pH 7.4, 150 mM NaCl, 0.5 mg/ml BSA,  2 mM DTT, 10 mM MgCl2,1x Halt phosphatase 
inhibitor cocktail and trace amounts of γ-32P ATP (20-40 µCi). For Km, ATP determination, 
TrkA and TrkB TKDs were assayed with variable ATP concentrations  (5 mM to 0.039 
mM) in the presence of fixed 2 mM peptide substrate and 10 mM MgCl2.  For Km, peptide 
determination, TrkA and TrkB TKDs were assayed with variable peptide concentrations 
(4 mM to 0.031 mM), fixed 2 mM ATP and 10 mM MgCl2. The protein concentration used 
for these experiments were 30 nM dephosphorylated TrkA-TKD, 400 nM 
dephosphorylated TrkB-TKD and 8 nM of both phosphorylated TrkA and phosphorylated 
TrkB TKDs.  
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Samples were taken at each time point, spotted onto pieces of P81 phosphocellulose 
squares (Millipore # 20-134), and immediately quenched with 0.5% phosphoric acid. The 
phosphocellulose squares were then washed extensively with 0.5% phosphoric acid and 
dried with acetone. A Tri-Carb 2900TR liquid scintillation analyzer (PerkinElmer) was 
used to measure the incorporated radioactivity of each phosphocellulose square. Initial 
rates were determined under conditions of <10% product formation – ensuring linearity – 
converted to specific activity, normalized for enzyme concentration and data fit to the 
Michaelis-Menten equation (vo = vmax[S]/(Km+[S])) using GraphPad Prism version 5.0. 
 
5.10. Radioactive autophosphorylation assays 
	  
Radioactive autophosphorylation assays were performed at RT with 4 µM of TrkA-TKD, 
TrkA KID, or TrkB TKD protein in the presence of 2mM ATP, 10 mM MgCl2 100 mM 
HEPES pH 7.4, 150 mM NaCl, 2 mM DTT, 1x Halt phosphatase inhibitor cocktail and 
trace amounts of γ-32P ATP (40 µCi). Samples taken at each time point were processed 
as above for the quantitative kinase assay samples. Counts from the scintillation 
analyzer were converted to moles of phosphate incorporated using measured γ-32P-ATP 
specific activity and then normalized to enzyme concentration. Each reaction data set 
was converted to percent maximum moles of phosphate incorporated normalized to 
enzyme concentration. 
Data were plotted and analyzed by several methods. Histogram plots were generated to 
compare relative moles of phosphate incorporated per mole of enzyme for time points 
from 0 to 5 minutes. A paired t test was used to compare data obtained with TrkA-TKD 
(n=3), TrkA KID-TKD (n=2), and TrkB-TKD (n=2), to determine statistical significance of 
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differences, with significance (P < 0.05) denoted with an asterisk. Data were also plotted 
and fitted with a four-parameter logistic equation to obtain time to half maximal 
autophosphorylation. Curves were fit to the 0 to 30 minute data. Histogram plots were 
used to compare the time to half maximal autophosphorylation for TrkA, TrkA KID, and 
TrkB TKDs. A paired t test was used to determine statistical significance (P < 0.05) 
denoted as an asterisk. GraphPad Prism version 5.0 was used to plot the data and 
perform the paired t tests.  
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